{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T20:32:46Z","timestamp":1769027566731,"version":"3.49.0"},"reference-count":206,"publisher":"Bentham Science Publishers Ltd.","issue":"20","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CTMC"],"published-print":{"date-parts":[[2020,8,17]]},"abstract":"<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>Gynecologic cancers, including cervical, primary peritoneal, ovarian, uterine\/endometrial,\nvaginal and vulvar cancers and gestational trophoblastic disease, are characterized by abnormal cell\nproliferation in female reproductive cells. Due to the variable pathology of these cancers and the lack\nof appropriate screening tests in developing countries, cancer diagnosis can be reported in advanced\nstages in most women and this situation adversely affects prognosis and clinical outcomes of illness.\nFor this reason, many researchers in the field of gynecological oncology have carried out many studies.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>The treatment of various gynecological problems, which cause physical, biological and psychosocial\nconditions such as fear, shame, blame and anger, has been important throughout the history. Treatment\nwith herbs has become popular nowadays due to the serious side effects of the synthetic drugs used in\ntreatment and the medical and economical problems caused by them. Many scientists have identified\nvarious active drug substances through in vivo and in vitro biological activity studies on medicinal\nplants from the past to the present. While the intrinsic complexity of natural product-based drug discoveries\nrequires highly integrated interdisciplinary approaches, scientific and technological advances\nand research trends clearly show that natural products will be among the most important new drug\nsources in the future.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>In this review, an overview of the studies conducted for the discovery of multitargeted drug molecules\nin the rational treatment of gynecological cancers is presented.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1568026620666200416084440","type":"journal-article","created":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T11:31:01Z","timestamp":1587036661000},"page":"1772-1790","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Roles of Medicinal Plants and Constituents in Gynecological Cancer Therapy: Current Literature and Future Directions"],"prefix":"10.2174","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5829-7869","authenticated-orcid":true,"given":"Esra K\u00fcpeli","family":"Akkol","sequence":"first","affiliation":[{"name":"Department of Pharmacognosy, Faculty of Pharmacy, Gazi University, Etiler 06330, Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7554-733X","authenticated-orcid":true,"given":"Fatma Tu\u011f\u00e7e G\u00fcra\u011fa\u00e7","family":"Dereli","sequence":"additional","affiliation":[{"name":"Department of Pharmacognosy, Faculty of Pharmacy, Gazi University, Etiler 06330, Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2790-2544","authenticated-orcid":true,"given":"Eduardo","family":"Sobarzo-S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Instituto de Investigacion e Innovacion en Salud, Facultad de Ciencias de la Salud, Universidad Central de Chile, 8330507 Santiago, Chile"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0895-0396","authenticated-orcid":true,"given":"Haroon","family":"Khan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Abdul Wali Khan University, Mardan 23200, Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","unstructured":"W.H.O. (WHO) . The World Health Organization\u2019s fight against cancer: Strategies that prevent, cure and care. Available from: https:\/\/www.who.int\/can cer\/publications\/fight_against_cancer\/en\/ (Accessed Nov 12,2019)","journal-title":"(WHO)"},{"key":"ref=2","author":"Boyle,P. .","unstructured":"Boyle,P.; Levin, B. World cancer report international agency for research on cancer ; IARC: Geneva. 2008,1-6","journal-title":"2008,1-6"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1007\/s00259-014-2732-8","volume":"41(7)","author":"Giammarile,F.","year":"2014","unstructured":"Giammarile,F.; Bozkurt, M.F.; Cibula,D.; Pahisa,J.; Oyen, W.J.; Paredes,P.; Olmos, R.V.; Sicart, S.V. The EANM clinical and technical guidelines for lymphoscintigraphy and sentinel node localization in gynaecological cancers. Eur, J. Nucl. Med. Mol. Imaging. 2014,41(7),1463-1477. http:\/\/dx.doi.org\/10.1007\/s00259-014-2732-8 PMID: 24609929","journal-title":"Eur, J.Nucl.Med.Mol.Imaging"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1002\/jso.21496","volume":"101(5)","author":"Mais,V.","year":"2010","unstructured":"Mais,V.; Peiretti,M.; Gargiulo,T.; Parodo,G.; Cirronis, M.G.; Melis, G.B. Intraoperative sentinel lymph node detection by vital dye through laparoscopy or laparotomy in early endometrial cancer, J. Surg. Oncol. 2010,101(5),408-412. http:\/\/dx.doi.org\/10.1002\/jso.21496 PMID: 20119976","journal-title":"Surg.Oncol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1200\/JCO.2007.14.0566","volume":"26(6)","author":"Van der Zee, A.G.","year":"2008","unstructured":"Van der Zee, A.G.; Oonk, M.H.; De Hullu, J.A.; Ansink, A.C.; Vergote,I.; Verheijen, R.H.; Maggioni,A.; Gaarenstroom, K.N.; Baldwin, P.J.; Van Dorst, E.B.; Van-der Velden,J.; Hermans, R.H.; van der Putten,H.; Drouin,P.; Schneider,A.; Sluiter, W.J. Sentinel node dissection is safe in the treatment of early-stage vulvar cancer, J. Clin. Oncol. 2008,26(6),884-889. http:\/\/dx.doi.org\/10.1200\/JCO.2007.14.0566 PMID: 18281661","journal-title":"Clin.Oncol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1097\/01.AOG.0000154885.44002.ae","volume":"105(3)","author":"Lu, K.H.","year":"2005","unstructured":"Lu, K.H.; Dinh,M.; Kohlmann,W.; Watson,P.; Green,J.; Syngal,S.; Bandipalliam,P.; Chen, L.M.; Allen,B.; Conrad,P.; Terdiman,J.; Sun,C.; Daniels,M.; Burke,T.; Gershenson, D.M.; Lynch,H.; Lynch,P.; Broaddus, R.R. Gynecologic cancer as a \u201csentinel cancer\u201d for women with hereditary nonpolyposis colorectal cancer syndrome. Obstet. Gynecol. 2005,105(3),569-574. http:\/\/dx.doi.org\/10.1097\/01.AOG.0000154885.44002.ae PMID: 15738026","journal-title":"Obstet.Gynecol"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"85","DOI":"10.18614\/deutfd.88761","volume":"28","author":"\u00dclger,E.","year":"2015","unstructured":"\u00dclger,E.; Alacacioglu,A.; G\u00fclseren, A.S.; Zencir,G.; Demir,L.; Tarhan, M.O. Psychosocial problems in cancer and the importance of psychosocial oncology. Deu Feas, J. 2015,28,85-92","journal-title":"Deu Feas, J"},{"key":"ref=8","author":"Weare,K","unstructured":"Weare.; K. Rehabilitation after gynecological cancer treatment. Int, J. Gynaecol. Obstet. 2015,131(2) (Suppl","journal-title":"Int, J.Gynaecol..Obstet"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/pon.3591","volume":"24(1)","author":"Hopman,P.","year":"2015","unstructured":"Hopman,P.; Rijken, M. Illness pe rceptions of cancer patients: relationships with illness characteristics and coping. Psychooncology. 2015,24(1),11-18. http:\/\/dx.doi.org\/10.1002\/pon.3591 PMID: 24891136","journal-title":"Psychooncology"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.ygyno.2014.03.019","volume":"133(3)","author":"R aimond,E.","year":"2014","unstructured":"R aimond,E.; Ballester,M.; Hudry,D.; Bendifallah,S.; Dara\u00ef, E.; Graesslin,O.; Coutant, C. Impact of sentinel lymph node biopsy on the therapeutic management of early-stage endometrial cancer: Results of a retrospective multicenter study. Gynecol. Oncol. 2014,133(3),506-511. http:\/\/dx.doi.org\/10.1016\/j.ygyno.2014.03.019 PMID: 24642092","journal-title":"Gynecol.Oncol"},{"key":"ref=11","author":"Baytop. .","unstructured":"Baytop.; T. Treatment Plant in Turkey: Past and Present; Nobel: Istanbul. 1999."},{"key":"ref=12","author":"Kara,H. .","unstructured":"Kara,H.; Aydin, S. Sexual problems and solutions; Sen Publishing: Ankara. 2002"},{"key":"ref=13","author":"G\u00fcrkan,E.","unstructured":"G\u00fcrkan,E.; \u00d6ndersev, D.V.; Ulusoylu,M.; G\u00f6ztas,Z.; Din\u00e7sahin, N. Herbal Treatment ; Marmara University Publications: Istanbul. 2003"},{"key":"ref=14","author":"\u00c7ubuk\u00e7u,B.","unstructured":"\u00c7ubuk\u00e7u,B.; Meri\u00e7li, A.H.; Mat,A.; Sariyar,G.; S\u00fctl\u00fcpinar,N.; Meri\u00e7li, F. Phytotherapy Supplementary Textbook; Istanbul University Faculty of Pharmacy: Istanbul. 2002"},{"key":"ref=15","author":"Asimgil. .","unstructured":"Asimgil.; A. Sifali Bitkiler; Timas Publishing Group: Istanbul. 1997."},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"5548","DOI":"10.1038\/sj.onc.1203957","volume":"19(49)","author":"Robinson, D.R.","year":"2000","unstructured":"Robinson, D.R.; Wu, Y.M.; Lin, S.F. The protein tyrosine kinase family of the human genome. Oncogene. 2000,19(49),5548-5557. http:\/\/dx.doi.org\/10.1038\/sj.onc.1203957 PMID: 11114734","journal-title":"Oncogene"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/35077225","volume":"411(6835)","author":"Blume-Jensen,P.","year":"2001","unstructured":"Blume-Jensen,P.; Hunter, T. Oncogenic kinase signalling. Nature. 2001,411(6835),355-365. http:\/\/dx.doi.org\/10.1038\/35077225 PMID: 11357143","journal-title":"Nature"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S0092-8674(00) 00114-8","volume":"103(2)","author":"Schlessinger,J","year":"2000","unstructured":"Schlessinger.; J. Cell signaling by receptor tyrosine kinases. Cell. 2000,103(2),211-225. http:\/\/dx.doi.org\/10.1016\/S0092-8674(00) 00114-8 PMID: 11057895","journal-title":"Cell"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/nrm1399","volume":"5(6)","author":"Hubbard,S.R","year":"2004","unstructured":"Hubbard.; S.R. Juxtamembrane autoinhib ition in receptor tyrosine kinases. Nat. Rev. Mol. Cell Biol. 2004,5(6),464-471. http:\/\/dx.doi.org\/10.1038\/nrm1399 PMID: 15173825","journal-title":"Nat.Rev.Mol.Cell Biol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/0092-8674(92) 90504-6","volume":"71(3)","author":"Pawson,T.","year":"1992","unstructured":"Pawson,T.; Gish, G.D. SH2 and SH3 domains: From structure to function. Cell. 1992,71(3),359-362. http:\/\/dx.doi.org\/10.1016\/0092-8674(92) 90504-6 PMID: 1423600","journal-title":"Cell"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1126\/science.8388123","volume":"260(5110)","author":"Brugge,J.S","year":"1993","unstructured":"Brugge.; J.S. New intracellular targets for therapeutic drug design. Science. 1993,260(5110),918-919. http:\/\/dx.doi.org\/10.1126\/science.8388123 PMID: 8388123","journal-title":"Science"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/S0065-7743(08) 60937-9","volume":"30","author":"Botfield, M.C.","year":"1995","unstructured":"Botfield, M.C.; Green, J. SH2 and SH3 domains: Choreographers of multiple signaling pathways. Annu. Rep. Med. Chem. 1995,30,227-237. http:\/\/dx.doi.org\/10.1016\/S0065-7743(08) 60937-9","journal-title":"Annu.Rep.Med.Chem"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/0092-8674(93) 90404-E","volume":"72(5)","author":"Songyang,Z.","year":"1993","unstructured":"Songyang,Z.; Shoelson, S.E.; Chaudhuri,M.; Gish,G.; Pawson,T.; Haser, W.G.; King,F.; Roberts,T.; Ratnofsky,S.; Lechleider, R.J.; Neel, B.G.; Birge, R.B.; Fajardo, J.E.; Chou, M.M.; Hanafusa,H.; Schaffhausen,B.; Cantley, L.C. SH2 domains recognize specific phosphopeptide sequences. Cell. 1993,72(5),767-778. http:\/\/dx.doi.org\/10.1016\/0092-8674(93) 90404-E PMID: 7680959","journal-title":"Cell"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1128\/MCB.14.4.2777","volume":"14(4)","author":"Songyang,Z.","year":"1994","unstructured":"Songyang,Z.; Shoelson, S.E.; McGlade,J.; Olivier,P.; Pawson,T.; Bustelo, X.R.; Barbacid,M.; Sabe,H.; Hanafusa,H.; Yi, T. Specific motifs recognized by the SH2 domains of Csk, 3BP2, fps\/fes, GRB-2, HCP, SHC, Syk, and Vav. Mol. Cell. Biol. 1994,14(4),2777-2785. http:\/\/dx.doi.org\/10.1128\/MCB.14.4.2777 PMID: 7511210","journal-title":"Mol.Cell.Biol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1146\/annurev.biochem.67.1.481","volume":"67","author":"Fruman, D.A.","year":"1998","unstructured":"Fruman, D.A.; Meyers, R.E.; Cantley, L.C. Phosphoinos itide kinases. Annu. Rev. Biochem. 1998,67,481-507. http:\/\/dx.doi.org\/10.1146\/annurev.biochem.67.1.481 PMID: 9759495","journal-title":"Annu.Rev.Biochem"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nrm2882","volume":"11(5)","author":"Vanhaesebroeck,B.","year":"2010","unstructured":"Vanhaesebroeck,B.; Guillermet-Guibert,J.; Graupera,M.; Bilanges, B. The emerging mechanisms of isoform-specific PI3K signalling. Nat. Rev. Mol. Cell Biol. 2010,11(5),329-341. http:\/\/dx.doi.org\/10.1038\/nrm2882 PMID: 20379207","journal-title":"Nat.Rev.Mol.Cell Biol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/nrc2443","volume":"8(9 )","author":"Amzel, L.M.","year":"2008","unstructured":"Amzel, L.M.; Huang, C.H.; Mandelker,D.; Lengauer,C.; Gabe-lli, S.B.; Vogelstein, B. Structural comparisons of class I phosphoinos itide 3-kinases. Nat. Rev. Cancer. 2008,8(9 ),665-669. http:\/\/dx.doi.org\/10.1038\/nrc2443 PMID: 18633356","journal-title":"Nat.Rev.Cancer"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"7809","DOI":"10.1073\/pnas.0700373104","volume":"104(19)","author":"Geering,B.","year":"2007","unstructured":"Geering,B.; Cutillas, P.R.; Nock,G.; Gharbi, S.I.; Vanhaesebroeck, B. Class IA phosphoinos itide 3-kinases are obligate p85-p110 heterodimers. Proc. Natl. Acad. Sci. USA. 2007,104(19),7809-7814. http:\/\/dx.doi.org\/10.1073\/pnas.0700373104 PMID: 17470792","journal-title":"Proc.Natl.Acad.Sci.USA"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1126\/science.1150799","volume":"318(5857)","author":"Huang, C.H.","year":"2007","unstructured":"Huang, C.H.; Mandelker,D.; Schmidt-Kittler,O.; Samuels,Y.; Velculescu, V.E.; Kinzler, K.W.; Vogelstein,B.; Gabelli, S.B.; Amzel, L.M. The structure of a human p110alpha\/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. Science. 2007,318(5857),1744-1748. http:\/\/dx.doi.org\/10.1126\/science.1150799 PMID: 18079394","journal-title":"Science"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/46319","volume":"402(6759)","author":"Walker, E.H.","year":"1999","unstructured":"Walker, E.H.; Perisic,O.; Ried,C.; Stephens,L.; Williams, R.L. Structural insights into phosphoinos itide 3-kinase catalysis and signalling. Nature. 1999,402(6759),313-320. http:\/\/dx.doi.org\/10.1038\/46319 PMID: 10580505","journal-title":"Nature"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1042\/bst0290846","volume":"29(Pt 6)","author":"Downes, C.P.","year":"2001","unstructured":"Downes, C.P.; Bennett,D.; McConnachie,G.; Leslie, N.R.; Pass,I.; MacPhee,C.; Patel,L.; Gray, A. Antagonism of PI 3-kinase-dependent signalling pathways by the tumour suppressor protein, PTEN. Biochem. Soc. Trans. 2001,29(Pt 6),846-851. http:\/\/dx.doi.org\/10.1042\/bst0290846 PMID: 11709086","journal-title":"Biochem.Soc.Trans"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"4240","DOI":"10.1073\/pnas.96.8.4240","volume":"96(8)","author":"Cantley, L.C.","year":"1999","unstructured":"Cantley, L.C.; Neel, B.G. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinos itide 3-kinase\/AKT pathway. Proc. Natl. Acad. Sci. USA. 1999,96(8),4240-4245. http:\/\/dx.doi.org\/10.1073\/pnas.96.8.4240 PMID: 10200246","journal-title":"Proc.Natl.Acad.Sci.USA"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.tem.2012.11.002","volume":"24(4)","author":"Ortega-Molina,A.","year":"2013","unstructured":"Ortega-Molina,A.; Serrano, M. PTEN in cancer, metabolism, and aging. Trends Endocrinol. Metab. 2013,24(4),184-189. http:\/\/dx.doi.org\/10.1016\/j.tem.2012.11.002 PMID: 23245767","journal-title":"Trends Endocrinol.Metab"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/nrm3330","volume":"13(5)","author":"Song, M.S.","year":"2012","unstructured":"Song, M.S.; Salmena,L.; Pandolfi, P.P. The functions and regulation of the PTEN tumour suppressor. Nat. Rev. Mol. Cell Biol. 2012,13(5),283-296. http:\/\/dx.doi.org\/10.1038\/nrm3330 PMID: 22473468","journal-title":"Nat.Rev.Mol.Cell Biol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ccr.2004.06.022","volume":"6(2)","author":"Nagata,Y.","year":"2004","unstructured":"Nagata,Y.; Lan, K.H.; Zhou,X.; Tan,M.; Esteva, F.J.; Sahin, A.A.; Klos, K.S.; Li,P.; Monia, B.P.; Nguyen, N.T.; Hortobagyi, G.N.; Hung, M.C.; Yu, D. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell. 2004,6(2),117-127. http:\/\/dx.doi.org\/10.1016\/j.ccr.2004.06.022 PMID: 15324695","journal-title":"Cancer Cell"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"e98851.","DOI":"10.1371\/journal.pone.0098851","volume":"9(6)","author":"S un,L.","year":"2014","unstructured":"S un,L.; Liu,J.; Yuan,Q.; Xing,C.; Yuan, Y. Association between PTEN Gene IVS4 polymorphism and risk of cancer: a meta-analysis. PLoS One. 2014,9(6),e98851. http:\/\/dx.doi.org\/10.1371\/journal.pone.0098851 PMID: 24901890","journal-title":"PLoS One"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1042\/BJ20150041","volume":"468(2)","author":"Risso,G.","year":"2015","unstructured":"Risso,G.; Blaustein,M.; Pozzi,B.; Mammi,P.; Srebrow, A. Akt\/PKB: one kinase, many modifications. Biochem, J. 2015,468(2),203-214. http:\/\/dx.doi.org\/10.1042\/BJ20150041 PMID: 25997832","journal-title":"Biochem, J"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0065-230X(05) 94002-5","volume":"94","author":"Bellacosa,A.","year":"2005","unstructured":"Bellacosa,A.; Kumar, C.C.; Di Cristofano,A.; Testa, J.R. Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv. Cancer Res. 2005,94,29-86. http:\/\/dx.doi.org\/10.1016\/S0065-230X(05) 94002-5 PMID: 16095999","journal-title":"Adv.Cancer Res"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1111\/bcp.13021","volume":"82(4)","author":"Mundi, P.S.","year":"2016","unstructured":"Mundi, P.S.; Sachdev,J.; McCourt,C.; Kalinsky, K. AKT in cancer: new molecular insights and advances in drug development. Br, J. Clin. Pharmacol. 2016,82(4),943-956. http:\/\/dx.doi.org\/10.1111\/bcp.13021 PMID: 27232857","journal-title":"Br, J.Clin.Pharmacol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3892\/ol.2016.4636","volume":"12(1)","author":"Xie,Y.","year":"2016","unstructured":"Xie,Y.; Naizabekov,S.; Chen,Z.; Tokay, T. Power of PTEN\/AKT: Molecular switch between tumor suppressors and oncogenes. Oncol. Lett. 2016,12(1),375-378. http:\/\/dx.doi.org\/10.3892\/ol.2016.4636 PMID: 27347153","journal-title":"Oncol.Lett"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1016\/j.cellsig.2011.05.004","volume":"23(10)","author":"Hers,I.","year":"2011","unstructured":"Hers,I.; Vincent, E.E.; Tavar\u00e9, J.M. Akt signalling in health and disease. Cell. Signal. 2011,23(10),1515-1527. http:\/\/dx.doi.org\/10.1016\/j.cellsig.2011.05.004 PMID: 21620960","journal-title":"Cell.Signal"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1016\/j.bbamcr.2012.08.017","volume":"1823(12)","author":"Martelli, A.M.","year":"2012","unstructured":"Martelli, A.M.; Tabellini,G.; Bressanin,D.; Ognibene,A.; Goto,K.; Cocco,L.; Evangelisti, C. The emerging mu ltiple roles of nuclear Akt. Biochim. Biophys. Acta. 2012,1823(12),2168-2178. http:\/\/dx.doi.org\/10.1016\/j.bbamcr.2012.08.017 PMID: 22960641","journal-title":"Biochim.Biophys.Acta"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1023\/B:APPT.0000045801.15585.dd","volume":"9(6)","author":"Osaki,M.","year":"2004","unstructured":"Osaki,M.; Oshimura,M.; Ito, H. PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis. 2004,9(6),667-676. http:\/\/dx.doi.org\/10.1023\/B:APPT.0000045801.15585.dd PMID: 15505410","journal-title":"Apoptosis"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/01.cco.0000198021.99347.b9","volume":"18(1)","author":"Samuels,Y.","year":"2006","unstructured":"Samuels,Y.; Ericson, K. Oncogenic PI3K and its role in cancer. Curr. Opin. Oncol. 2006,18(1),77-82. http:\/\/dx.doi.org\/10.1097\/01.cco.0000198021.99347.b9 PMID: 16357568","journal-title":"Curr.Opin.Oncol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s10787-017-0336-1","volume":"25( 3)","author":"Kaur,A.","year":"2017","unstructured":"Kaur,A.; Sharma, S. Mammalian target of rapamycin (mTOR)  as a potential therapeutic target in various diseases. Inflammopharma. 2017,25( 3),293-312. http:\/\/dx.doi.org\/10.1007\/s10787-017-0336-1 PMID: 28417246","journal-title":"Inflammopharma"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","volume":"149(2)","author":"Laplante,M.","year":"2012","unstructured":"Laplante,M.; Sabatini, D.M. mTOR signaling in growth control and disease. Cell. 2012,149(2),274-293. http:\/\/dx.doi.org\/10.1016\/j.cell.2012.03.017 PMID: 22500797","journal-title":"Cell"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2119\/2005-00029.Sa ltiel","volume":"10(7-12)","author":"Chang,L.","year":"2004","unstructured":"Chang,L.; Chiang, S.H.; Saltiel, A.R. Insulin signaling and the regulation of glucose transport. Mol. Med. 2004,10(7-12),65-71. http:\/\/dx.doi.org\/10.2119\/2005-00029.Sa ltiel PMID: 16307172","journal-title":"Mol.Med"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2174\/157339913804143225","volume":"9(1)","author":"Fu,Z.","year":"2013","unstructured":"Fu,Z.; Gilbert, E.R.; Liu, D. Regulation of insulin synthesis and secretion and pancreatic Beta-cell dysfunction in diabetes. Curr. Diabetes Rev. 2013,9(1),25-53. http:\/\/dx.doi.org\/10.2174\/157339913804143225 PMID: 22974359","journal-title":"Curr.Diabetes Rev"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.cell.2013.11.049","volume":"156(4)","author":"Menon,S.","year":"2014","unstructured":"Menon,S.; Dibble, C.C.; Talbott,G.; Hoxhaj,G.; Valvezan, A.J.; Takahashi,H.; Cantley, L.C.; Manning, B.D. Spatial control of the TSC complex integrates insulin and nutrient regulation of mTORC1 at the lysosome. Cell. 2014,156(4),771-785. http:\/\/dx.doi.org\/10.1016\/j.cell.2013.11.049 PMID: 24529379","journal-title":"Cell"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"28495","DOI":"10.1074\/jbc","volume":"270(48)","author":"Newton,A.C","year":"1995","unstructured":"Newton.; A.C. Protein kinase C: structure, function, and regulation, J. Biol. Chem. 1995,270(48),28495-28498. http:\/\/dx.doi.org\/10.1074\/jbc","journal-title":"Biol.Chem"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nrd2062","volume":"5(8)","author":"Faivre,S.","year":"2006","unstructured":"Faivre,S.; Kroemer,G.; Raymond, E. Current development of mTOR inhibitors as anticancer agents. Nat. Rev. Drug Discov. 2006,5(8),671-688. http:\/\/dx.doi.org\/10.1038\/nrd2062 PMID: 16883305","journal-title":"Nat.Rev.Drug Discov"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1586\/erm.09.8","volume":"9(3)","author":"Wysocki,P.J","year":"2009","unstructured":"Wysocki.; P.J. mTOR in renal cell cancer: modulator of tumor biology and therapeutic target. Expert Rev. Mol. Diagn. 2009,9(3),231-241. http:\/\/dx.doi.org\/10.1586\/erm.09.8 PMID: 19379082","journal-title":"Expert Rev.Mol.Diagn"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/nature04869","volume":"441(7092)","author":"Shaw, R.J.","year":"2006","unstructured":"Shaw, R.J.; Cantley, L.C.; Ras. PI(3) K and mTOR signalling controls tumour cell growth. Nature. 2006,441(7092),424-430. http:\/\/dx.doi.org\/10.1038\/nature04869 PMID: 16724053","journal-title":"Nature"},{"key":"ref=54","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2005.08.008","author":"Hay,N","unstructured":"Hay.; N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell. 2005,8(3),179-183. http:\/\/dx.doi.org\/10.1016\/j.ccr.2005.08.008 PMID: 16169463 [ 55] Pawson, T. Introduction: protein kinases. FASEB J","journal-title":"Cancer Cell"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.molcel.2007.03.003","volume":"25(6)","author":"Sancak,Y.","year":"2007","unstructured":"Sancak,Y.; Thoreen, C.C.; Peterson, T.R.; Lindquist, R.A.; Kang, S.A.; Spooner,E.; Carr, S.A.; Sabatini, D.M. PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol. Cell. 2007,25(6),903-915. http:\/\/dx.doi.org\/10.1016\/j.molcel.2007.03.003 PMID: 17386266","journal-title":"Mol.Cell"},{"key":"ref=57","author":"Figlin, R.A.","unstructured":"Figlin, R.A.; Brown,E.; Armstrong, A.J.; Akerley,W.; Benson, A.B. III.; Burstein, H.J.; Ettinger, D.S.; Febbo, P.G.; Fury, M.G.; Hudes, G.R.; Kies, M.S.; Kwak, E.L.; Morgan, R.J. Jr; Mortimer,J.; Reckamp,K.; Venook, A.P.; Worden,F.; Yen, Y. NCCN Task Force Report: mTOR inhibition in solid tumors, J. Natl. Compr. Canc. Netw. 2008,6 (5) (Suppl. 5),S1-S20. PMID: 18926092","journal-title":"J..Natl.Compr.Canc.Netw"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1126\/science.1106148","volume":"307(5712)","author":"Sarbassov, D.D.","year":"2005","unstructured":"Sarbassov, D.D.; Guertin, D.A.; Ali, S.M.; Sabatini, D.M. Phosphorylation and regulation of Akt\/PKB by the rictor-mTOR complex. Science. 2005,307(5712),1098-1101. http:\/\/dx.doi.org\/10.1126\/science.1106148 PMID: 15718470","journal-title":"Science"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.2214\/AJR.14.12695","volume":"205(6)","author":"Micc\u00f2, M.","year":"2015","unstructured":"Micc\u00f2, M.; Sala,E.; Lakhman,Y.; Hricak,H.; Vargas, H.A. Imaging features of uncommon gynecologic cancers. AJR Am, J. Roentgenol. 2015,205(6),1346-1359. http:\/\/dx.doi.org\/10.2214\/AJR.14.12695 PMID: 26587944","journal-title":"AJR Am, J.Roentgenol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3322\/canjclin.57.1.43","volume":"57(1)","author":"Jemal,A.","year":"2007","unstructured":"Jemal,A.; Siegel,R.; Ward,E.; Murray,T.; Xu,J.; Thun, M.J. Cancer statistics. 2007. CA Cancer J. Clin. 2007,57(1),43-66. http:\/\/dx.doi.org\/10.3322\/canjclin.57.1.43 PMID: 17237035","journal-title":"CA Cancer J.Clin"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"678.e1","DOI":"10.1016\/j.ajog.2007.09.053","volume":"197(6)","author":"Bader, A.A.","year":"2007","unstructured":"Bader, A.A.; Winter,R.; Haas,J.; Tamussino, K.F. Where to look for the sentinel lymph node in cervical cancer. Am, J. Obstet. Gynecol. 2007,197(6),678.e1-678.e7. http:\/\/dx.doi.org\/10.1016\/j.ajog.2007.09.053 PMID: 18060980","journal-title":"Am, J.Obstet.Gynecol"},{"key":"ref=62","author":"Eifel, P.J.","unstructured":"Eifel, P.J.; Winter,K.; Morris,M.; Levenback,C.; Grigsby, P.W.; Cooper,J.; Rotman,M.; Gershenson,D.; Mutch, D.G. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG). 90-01. J. Clin. Oncol. 2004,22(5),872-880. ht tp:\/\/dx.doi.org\/10.1200\/JCO.2004.07.197 PMID: 14990643","journal-title":"90-01"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.ygyno.2005.04.016","volume":"98(2)","author":"Rob,L.","year":"2005","unstructured":"Rob,L.; Strnad,P.; Robova,H.; Charvat,M.; Pluta,M.; Schlegerova,D.; Hrehorcak, M. Study of lymphatic mapping and sentinel node identification in early stage cervical cancer. Gynecol. Oncol. 2005,98(2),281-288. http:\/\/dx.doi.org\/10.1016\/j.ygyno.2005.04.016 PMID: 15961145","journal-title":"Gynecol.Oncol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1002\/(SICI)","volume":"86(3)","author":"Vizcaino, A.P.","year":"2000","unstructured":"Vizcaino, A.P.; Moreno,V.; Bosch, F.X.; Mu\u00f1oz,N.; Barros-Dios, X.M.; Borras,J.; Parkin, D.M. International trends in incidence of cervical cancer: II. Squamous-cell carcinoma. Int, J. Cancer. 2000,86(3),429-435. http:\/\/dx.doi.org\/10.1002\/(SICI). 1097-","journal-title":"Squamous-cell carcinoma.Int, J.Cancer"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.amjsurg.2007.10.021","volume":"197(1)","author":"Barranger,E.","year":"2009","unstructured":"Barranger,E.; Delpech,Y.; Coutant,C.; Dubernard,G.; Uzan,S.; Darai, E. Laparoscopic sentinel node mapping using combined detection for endometrial cancer: a study of 33 cases--is it a promising technique? Am, J. Surg. 2009,197(1),1-7. http:\/\/dx.doi.org\/10.1016\/j.amjsurg.2007.10.021 PMID: 18558387","journal-title":"Surg"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.critrevonc.2011.04.004","volume":"81(3)","author":"Di,Donato,V","year":"2012","unstructured":"Di Donato,V.; Bellati,F.; Fischetti,M.; Plotti,F.; Perniola,G.; Panici, P.B. Vaginal cancer. Crit. Rev. Oncol. Hematol. 2012,81(3),286-295. http:\/\/dx.doi.org\/10.1016\/j.critrevonc.2011.04.004 PMID: 21571543","journal-title":"Crit.Rev.Oncol.Hematol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.ygyno.2010.10.009","volume":"120(2)","author":"Crane, L.M.","year":"2011","unstructured":"Crane, L.M.; Themelis,G.; Arts, H.J.; Buddingh, K.T.; Brouwers, A.H.; Ntziachristos,V.; van Dam, G.M.; van der Zee, A.G. Intraoperative near-infrared fluorescence imaging for sentinel lymph node detection in vulvar cancer: first clinical results. Gynecol. Oncol. 2011,120(2),291-295. http:\/\/dx.doi.org\/10.1016\/j.ygyno.2010.10.009 PMID: 21056907","journal-title":"Gynecol.Oncol"},{"key":"ref=68","first-page":"1269","volume":"66(7)","author":"Canavan, T.P.","year":"2002","unstructured":"Canavan, T.P.; Cohen, D. Vulvar cancer. Am. Fam. Physician. 2002,66(7),1269-1274. PMID: 12387439","journal-title":"Am.Fam..Physician"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1006\/gyno.1995.1151","volume":"57(3)","author":"Burger, M.P.","year":"1995","unstructured":"Burger, M.P.; Hollema,H.; Emanuels, A.G.; Krans,M.; Pras,E.; Bouma, J. The importance of the groin node status for the survival of T1 and T2 vulval carcinoma patients. Gynecol. Oncol. 1995,57(3),327-334. http:\/\/dx.doi.org\/10.1006\/gyno.1995.1151 PMID: 7774836","journal-title":"Gynecol.Oncol"},{"key":"ref=70","first-page":"163","volume":"84(2)","author":"Levenback,C.","year":"1994","unstructured":"Levenback,C.; Burke, T.W.; Gershenson, D.M.; Morris,M.; Malpica,A.; Ross, M.I. Intraoperative lymphatic mapping for vulvar cancer. Obstet. Gynecol. 1994,84(2),163-167. PMID: 8041523","journal-title":"Obstet.Gynecol"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1006\/gyno.1995.0011","volume":"59(2 )","author":"Levenback,C.","year":"1995","unstructured":"Levenback,C.; Burke, T.W.; Morris,M.; Malpica,A.; Lucas, K.R.; Gershenson, D.M. Potential applications of intraoperative lymphatic mapping in vulvar cancer. Gynecol. Oncol. 1995,59(2 ),216-220. http:\/\/dx.doi.org\/10.1006\/gyno.1995.0011 PMID: 7590476","journal-title":"Gynecol.Oncol"},{"key":"ref=72","author":"Beard, C.M.","unstructured":"Beard, C.M.; Hartmann, L.C.; Atkinson, E.J.; O\u2019Brien, P.C.; Malkasian, G.D.; Keeney, G.L.; Melton, L.J. III The epidemiology of ovarian cancer: a population-based study in Olmsted County, Minnesota. 1935-1991. Ann. Epidemiol. 2000,10(1),14-23. http:\/\/dx.doi.org\/10.1016\/S1047-2797(99) 00045-9 PMID: 10658685","journal-title":"1935-1991"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.bpobgyn.2005.10.016","volume":"20(2)","author":"Hanna,L.","year":"2006","unstructured":"Hanna,L.; Adams, M. Prevention of ovarian cancer. Best Pract. Res. Clin. Obstet. Gynaecol. 2006,20(2),339-362. http:\/\/dx.doi.org\/10.1016\/j.bpobgyn.2005.10.016 PMID: 16368271","journal-title":"Best Pract.Res.Clin.Obstet.Gynaecol"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.critrevonc.2006.03.004","volume":"60(2)","author":"Colombo,N.","year":"2006","unstructured":"Colombo,N.; Van Gorp,T.; Parma,G.; Amant,F.; Gatta,G.; Sessa,C.; Vergote, I. Ovarian cancer. Crit. Rev. Oncol. Hematol. 2006,60(2),159-179. http:\/\/dx.doi.org\/10.1016\/j.critrevonc.2006.03.004 PMID: 17018256","journal-title":"Crit.Rev.Oncol.Hematol"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1359-6349(07) 70013-7","volume":"1","author":"Poveda,A","year":"2007","unstructured":"Poveda.; A. Management of recurrent ovarian cancer with systemic therapy. EJC Supplements. 2007,1,29-36. http:\/\/dx.doi.org\/10.1016\/S1359-6349(07) 70013-7","journal-title":"EJC Supplements"},{"key":"ref=76","first-page":"21","volume":"288","author":"Rossouw, J.E.","year":"2002","unstructured":"Rossouw, J.E.; Anderson, G.L.; Prentice, R.L. Writing group for the women\u2019s health initiative investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women\u2019s health initiative ra ndomized controlled trial,J. AMA. 2002,288,21-333","journal-title":",J..AMA"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1200\/JCO.2012.45.5758","volume":"31(17)","author":"Yang, H.P.","year":"2013","unstructured":"Yang, H.P.; Anderson, W.F.; Rosenberg, P.S.; Trabert,B.; Gierach, G.L.; Wentzensen,N.; Cronin, K.A.; Sherman, M.E. Ovarian cancer incidence trends in relation to changing patterns of menopausal hormone therapy use in the United States, J. Clin. Oncol. 2013,31(17),2146-2151. http:\/\/dx.doi.org\/10.1200\/JCO.2012.45.5758 PMID: 23650423","journal-title":"Clin.Oncol"},{"key":"ref=78","first-page":"48","volume":"2","author":"\u00d6zcan,S.","year":"2009","unstructured":"\u00d6zcan,S.; Kurdak,H.; Bozdemir, N. Servikal kanser taramasi. Turkish Journal of Family Practice. 2009,2,48-51","journal-title":"Turkish Journal of Family Practice"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.ijgo.2009.03.027","volume":"106(2)","author":"Cain, J.M.","year":"2009","unstructured":"Cain, J.M.; Ngan,H.; Garland,S.; Wright, T. FIGO Working Group on Combating Cervical Cancer. Control of cervical cancer: women\u2019s options and rights. Int, J. Gynaecol. Obstet. 2009,106(2),141-143. http:\/\/dx.doi.org\/10.1016\/j.ijgo.2009.03.027 PMID: 19535071","journal-title":"Int, J.Gynaecol.Obstet"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1016\/j.ejca.2009.07.018","volume":"45( 15)","author":"Arbyn,M.","year":"2009","unstructured":"Arbyn,M.; Raifu, A.O.; Weiderpass,E.; Bray,F.; Anttila, A. Trends of cervical cancer mortality in the member states of the European Union. Eur, J. Cancer. 2009,45( 15),2640-2648. http:\/\/dx.doi.org\/10.1016\/j.ejca.2009.07.018 PMID: 19695864","journal-title":"Eur, J.Cancer"},{"key":"ref=81","author":"Dunleavey. .","unstructured":"Dunleavey.; R. Cervical cancer: A guide for nurses ; John Wiley and Sons: London. 2009.","journal-title":""},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.ygyno.2011.08.010","volume":"123(2)","author":"Bats, A.S.","year":"2011","unstructured":"Bats, A.S.; Bu\u00e9nerd,A.; Querleu,D.; Leblanc,E.; Dara\u00ef, E.; Morice,P.; Marret,H.; Gillaizeau,F.; Mathevet,P.; L\u00e9curu, F. SENTICOL collaborative group. Diagnostic value of intraoperative examination of sentinel lymph node in early cervical cancer: a prospective, multicenter study. Gynecol. Oncol. 2011,123(2),230-235. http:\/\/dx.doi.org\/10.1016\/j.ygyno.2011.08.010 PMID: 21893335","journal-title":"Gynecol.Oncol"},{"key":"ref=83","first-page":"34","volume":"16","author":"Polat,A.","year":"2000","unstructured":"Polat,A.; Aydin, \u00d6.; D\u00fcsmez, D. Mersin ilinde 1989-1999 yillari arasinda g\u00f6r\u00fclen kadin genital sistem t\u00fcm\u00f6rlerinin dagiliminin degerlendirilmesi. Turkish J. Path. 2000,16,34-38","journal-title":"Turkish J..Path"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"11","DOI":"10.332 2\/caac.21166","volume":"63(1)","author":"Siegel,R.","year":"2013","unstructured":"Siegel,R.; Naishadham,D.; Jemal, A. Cancer statistics. 2013. CA Cancer J. Clin. 2013,63(1),11-30. http:\/\/dx.doi.org\/10.332 2\/caac.21166 PMID: 23335087","journal-title":"CA Cancer J.Clin"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1038\/sj.bjc.6603469","volume":"95(11)","author":"Villa, L.L.","year":"2006","unstructured":"Villa, L.L.; Costa, R.L.R.; Petta, C.A.; Andrade, R.P.; Paa-vonen,J.; Iversen, O.E.; Olsson, S.E.; H\u00f8ye,J.; Steinwall,M.; Riis-Johannessen,G.; Andersson-Ellstrom,A.; Elfgren,K.; Krogh, Gv.; Lehtinen,M.; Malm,C.; Tamms, G.M.; Giacole tti,K.; Lupin acci,L.; Railkar,R.; Taddeo, F.J.; Bryan,J.; Esser, M.T.; Sings, H.L.; Saah, A.J.; Barr, E. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6\/11\/16\/18 L1 virus-like particle vaccine through 5 years of follow-up. Br, J. Cancer. 2006,95(11),1459-1466. http:\/\/dx.doi.org\/10.1038\/sj.bjc.6603469 PMID: 17117182","journal-title":"Br, J.Cancer"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.ygyno.2003.11.048","volume":"92(3)","author":"Keys, H.M.","year":"2004","unstructured":"Keys, H.M.; Roberts, J.A.; Brunetto, V.L.; Zaino, R.J.; Spirtos, N.M.; Bloss, J.D.; Pearlman,A.; Maiman, M.A.; Bell, J.G. Gynecologic Oncology Group. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. 2004,92(3),744-751. http:\/\/dx.doi.org\/10.1016\/j.ygyno.2003.11.048 PMID: 14984936","journal-title":"Gynecol.Oncol"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0140-6736(05) 67063-8","volume":"366(9484)","author":"Amant,F.","year":"2005","unstructured":"Amant,F.; Moerman,P.; Neven,P.; Timmerman,D.; Van Limbergen,E.; Vergote, I. Endometrial cancer. Lancet. 2005,366(9484),491-505. http:\/\/dx.doi.org\/10.1016\/S0140-6736(05) 67063-8 PMID: 16084259","journal-title":"Lancet"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1053\/beog.2000.0180","volume":"15(3)","author":"Purdie, D.M.","year":"2001","unstructured":"Purdie, D.M.; Green, A.C. Epidemiology of endometrial cancer. Best Pract. Res. Clin. Obstet. Gynaecol. 2001,15(3),341-354. http:\/\/dx.doi.org\/10.1053\/beog.2000.0180 PMID: 11476557","journal-title":"Best Pract.Res.Clin.Obstet.Gynaecol"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.ygyno.2007.11.011","volume":"108(3)","author":"Stroup, A.M.","year":"2008","unstructured":"Stroup, A.M.; Harlan, L.C.; Trimble, E.L. Demographic, clinical, and treatment trends among women diagnosed with vulvar cancer in the United States. Gynecol. Oncol. 2008,108(3),577-583. http:\/\/dx.doi.org\/10.1016\/j.ygyno.2007.11.011 PMID: 18155274","journal-title":"Gynecol.Oncol"},{"key":"ref=90","first-page":"6","volume":"2","author":"Olaitan,A.","year":"2002","unstructured":"Olaitan,A.; Murdoch, J. Clinical management of vulval cancer. Rev. Gyn. Prac. 2002,2,6-22","journal-title":"Rev.Gyn..Prac"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1038\/bjc.2014.205","volume":"110(12)","author":"Meads,C.","year":"2014","unstructured":"Meads,C.; Sutton, A.J.; Rosenthal, A.N.; Malysiak,S.; Kowalska,M.; Zapalska,A.; Rogozinska,E.; Baldwin,P.; Ganesan,R.; Borowiack,E.; Barton,P.; Roberts,T.; Khan,K.; Sundar, S. Sentinel lymph node biopsy in vulval cancer: Systematic review and meta-analysis. Br, J. Cancer. 2014,110(12),2837-2846. http:\/\/dx.doi.org\/10.1038\/bjc.2014.205 PMID: 24867697","journal-title":"Br, J.Cancer"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.ygyno.2009.01.004","volume":"113(3)","author":"Moore,D.H","year":"2009","unstructured":"Moore.; D.H. Chemotherapy and radiation therapy in the treatment of squamous cell carcinoma of the vulva: Are two therapies better than one? Gynecol. Oncol. 2009,113(3),379-383. http:\/\/dx.doi.org\/10.1016\/j.ygyno.2009.01.004 PMID: 19232700","journal-title":"Oncol"},{"key":"ref=93","unstructured":"International Cancer Research Partnership. Gynecologic cancers portfolio analysis. Available from: https:\/\/www.icrpartnership.org\/ library\/file\/3\/ICRP_GYN_analysis.pdf (Accessed Nov 12,2019)"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"288","DOI":"10.6004\/jnccn.2014.0026","volume":"12(2)","author":"Abu-Rustum.","year":"2014","unstructured":"Abu-Rustum.; N.R. Sentinel lymph node mapping for endometrial cancer: a modern approach to surgical staging, J. Natl. Compr. Canc. Netw. 2014,12(2),288-297. http:\/\/dx.doi.org\/10.6004\/jnccn.2014.0026 PMID: 24586087","journal-title":"Natl.Compr.Canc.Netw"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1111\/IGC.0b013e3181a1c0b1","volume":"19(3)","author":"Robova,H.","year":"2009","unstructured":"Robova,H.; Charvat,M.; Strnad,P.; Hrehorcak,M.; Taborska,K.; Skapa,P.; Rob, L. Lymphatic mapping in endometrial cancer: comparison of hysteroscopic and subserosal injection and the distribution of sentinel lymph nodes. Int, J. Gynecol. Cancer. 2009,19(3),391-394. http:\/\/dx.doi.org\/10.1111\/IGC.0b013e3181a1c0b1 PMID: 19407565","journal-title":"Int, J.Gynecol.Cancer"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/cncr.30418","volume":"123(2)","author":"Miller,D.S","year":"2017","unstructured":"Miller.; D.S. Patients with e ndom etrial cancer at risk for lymphatic metastasis should undergo pelvic and periaortic lymphadenectomy as part of their initial surgery. Cancer. 2017,123(2),192-196. http:\/\/dx.doi.org\/10.1002\/cncr.30418 PMID: 28067950","journal-title":"Cancer"},{"key":"ref=97","author":"Tuncer,Z.S","unstructured":"Tuncer.; Z.S. What is cervical cancer? Symptoms and treatment methods; G\u00fcnalp,S.; Tuncer, S. Eds.; Pelikan Publishing: Ankara. 2004,669-682","journal-title":"Eds..; Pelikan Publishing: Ankara"},{"key":"ref=98","author":"Tuncer,S.","unstructured":"Tuncer,S.; Salman, M.\u00c7. Gynecology and Obstetrics ; G\u00fcnalp,S.; Tuncer, S. Eds.; Pelikan Publishing: Ankara. 2004,653-668","journal-title":"Eds..; Pelikan Publishing: Ankara"},{"key":"ref=99","first-page":"1","volume":"14(1)","author":"Zemheri,E. .","year":"2005","unstructured":"Zemheri,E.; Koyuncuer, A. The importance of Pap test in early diagnosis of cervical cancers. STED. 2005,14(1),1-4","journal-title":"STED"},{"key":"ref=100","first-page":"97","volume":"9","author":"Barut. .","year":"2000","unstructured":"Barut.; A. Early diagnosis and treatment in cervical cancer. STED. 2000,9,97","journal-title":"STED"},{"key":"ref=101","author":"Brinton, L.A.","unstructured":"Brinton, L.A.; Lacey, J.V.; Sherman, M.E. Epidemiology of gynecologic cancers. In: Principles and Practice of Gynecologic Oncology; Hoskins, W.J. Ed.; Lippincott Williams and Wilkins: Philadelphia. 2005,3-9","journal-title":"In: Principles and Practice of Gynecologic Oncology; Hoskins, W.J.Ed..; Lippincott Williams and Wilkins: Philadelphia"},{"key":"ref=102","author":"Atas\u00fc, T. .","unstructured":"Atas\u00fc, T.; Sahmay, S. Gynecology ; Nobel: Istanbul. 2001","journal-title":"2001"},{"key":"ref=103","first-page":"281","volume":"20(5)","author":"Ko\u00e7, F.","year":"2010","unstructured":"Ko\u00e7, F.; Aksit,S.; Kurug\u00f6l,Z.; Koturoglu,G.; Halicioglu,O.; Aslan, A. Cervical cancer; Are women physicians well aware?. Turkiye Klinikleri J. Gynecol. Obst. 2010,20(5),281-286","journal-title":"Turkiye Klinikleri J.Gynecol..Obst"},{"key":"ref=104","author":"\u00d6zg\u00fcl. .","unstructured":"\u00d6zg\u00fcl.; N. Cases of cervical cancer and cervical cancer in Turkey screening studies; Onur Publishing: Ankara. 2007."},{"key":"ref=105","first-page":"885","volume":"101(5 Pt 1)","author":"Tingulstad,S.","year":"2003","unstructured":"Tingulstad,S.; Skjeldestad, F.E.; Halvorsen, T.B.; Hagen, B. Survival and prognostic factors in patients with ovarian cancer. Obstet. Gynecol. 2003,101(5 Pt 1),885-891. PMID: 12738145","journal-title":"Obstet.Gynecol"},{"key":"ref=106","author":"Cibula,D.","unstructured":"Cibula,D.; Abu-Rustum, N.R.; Dusek,L.; Zik\u00e1n,M.; Zaal,A.; Sevcik,L.; Kenter, G.G.; Querleu,D.; Jach,R.; Bats, A.S.; Dyduch,G.; Graf,P.; Klat,J.; Lacheta,J.; Meijer, C.J.; Mery,E.; Verheijen,R.; Zweemer, R.P. Prognostic significance of low. ume sentinel lymph node disease in early-stage cervical cancer. Gynecol. Oncol. 2012,124(3),496-501. http:\/\/dx.doi.org\/10.1016\/j.ygyno.2011.11.037 PMID: 22120175","journal-title":"cervical cancer"},{"key":"ref=107","author":"C oggon,D.","unstructured":"C oggon,D.; Harris, E.C.; Brown,T.; Rice,T.; Palmer, K.T. Occupational mortality in England and Wales ; Office of Public Sector Information: London. 2009"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1002\/cncr.31551","volume":"124(13)","author":"Cronin, K.A.","year":"2018","unstructured":"Cronin, K.A.; Lake, A.J.; Scott,S.; Sherman, R.L.; Noone, A.M.; Howlader,N.; Henley, S.J.; Anderson, R.N.; Firth, A.U.; Ma,J.; Kohler, B.A.; Jemal, A. Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics. Cancer. 2018,124(13),2785-2800. http:\/\/dx.doi.org\/10.1002\/cncr.31551 PMID: 29786848","journal-title":"Cancer"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"445","DOI":"10.3892\/ijo.2014.2764","volume":"46(2)","author":"Sayasneh,A.","year":"2015","unstructured":"Sayasneh,A.; Ekechi,C.; Ferrara,L.; Kaijser,J.; Stalder,C.; Sur,S.; Timmerman,D.; Bourne, T. The characteristic ultrasound features of specific types of ovarian pathology (review) . Int, J. Oncol. (review). 2015,46(2),445-458. http:\/\/dx.doi.org\/10.3892\/ijo.2014.2764 PMID: 25406094","journal-title":"Int, J.Oncol.(review)"},{"key":"ref=110","unstructured":"Gynecologic cancers. What are the symptoms?. Available on: www.cdc.gov\/cancer\/gynecologic\/basic_info\/symptoms.html (Accessed Nov 12,2019)"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.ygyno.2013.09.007","volume":"131(3)","author":"Math\u00e9ron, H.M.","year":"2013","unstructured":"Math\u00e9ron, H.M.; van den Berg, N.S.; Brouwer, O.R.; Kleinjan, G.H.; van Driel, W.J.; Trum, J.W.; Vegt,E.; Kenter,G.; van Leeuwen, F.W.; Vald\u00e9s Olmos, R.A. Multimodal surgical guidance towards the sentinel node in vulvar cancer. Gynecol. Oncol. 2013,131(3),720-725. http:\/\/dx.doi.org\/10.1016\/j.ygyno.2013.09.007 PMID: 24051219","journal-title":"Gynecol.Oncol"},{"key":"ref=112","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2011.07.039","author":"Hutteman,M.","unstructured":"Hutteman,M.; van der Vorst, J.R.; Gaarenstroom, K.N.; Peters, A.A.; Mieog, J.S.; Schaafsma, B.E.; Lowik, C.W.; Frangioni, J.V.; van de Velde, C.J.; Vahrmeijer, A.L. Optimization of near-infrared fluorescent sentinel lymph node mapping for vulvar cancer. Am, J. Obstet. Gynecol. 2012,206(1),89,1-5. http:\/\/dx.doi.org\/10.1016\/j.ajog.2011.07.039","journal-title":"Am, J.Obstet.Gynecol"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1200\/JCO.2010.32.0432","volume":"29(13)","author":"L\u00e9curu,F.","year":"2011","unstructured":"L\u00e9curu,F.; Mathevet,P.; Querleu,D.; Leblanc,E.; Morice,P.; Dara\u00ef, E.; Marret,H.; Magaud,L.; Gillaizeau,F.; Chatellier,G.; Dargent, D. Bilateral negative sentinel nodes accurately predict absence of lymph node metastasis in early cervical cancer: results of the SENTICOL study, J. Clin. Oncol. 2011,29(13),1686-1691. http:\/\/dx.doi.org\/10.1200\/JCO.2010.32.0432 PMID: 21444878","journal-title":"Clin.Oncol"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ygyno.2007.02.008","volume":"105(2)","author":"Hauspy,J.","year":"2007","unstructured":"Hauspy,J.; Beiner,M.; Harley,I.; Ehrlich,L.; Rasty,G.; Covens, A. Sentinel lymph nodes in early stage cervical cancer. Gynecol. Oncol. 2007,105(2),285-290. http:\/\/dx.doi.org\/10.1016\/j.ygyno.2007.02.008 PMID: 17368525","journal-title":"Gynecol.Oncol"},{"key":"ref=115","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ygyno.2009.06.017","volume":"115 (1)","author":"Cibula,D.","year":"2009","unstructured":"Cibula,D.; Kuzel,D.; Sl\u00e1ma,J.; Fischerova,D.; Dundr,P.; Freitag,P.; Zik\u00e1n,M.; Pavlista,D.; Tomancova, V. Sentinel node (SLN)  biopsy in the management of locally advanced cervical cancer. Gynecol. Oncol. 2009,115 (1),46-50. ht tp:\/\/dx.doi.org\/10.1016\/j.ygyno.2009.06.017 PMID: 19646741","journal-title":"Gynecol.Oncol"},{"key":"ref=116","first-page":"1","volume":"109","year":"2009","unstructured":"ACOG Committee on Practice Bulletins. ACOG practice bulletin: Clinical management guidelines for obstetrician-gynecologists. Obstet. Gynecol. 2009,109,1-12","journal-title":"Obstet..Gynecol"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.ajog.2016.11.1033","volume":"216(5)","author":"Bodurtha,Smith.","year":"2017","unstructured":"Bodurtha Smith, A.J.; Fader, A.N.; Tanner, E.J. Sentinel lymph node assessment in endometrial cancer: a systematic review and meta-analysis. Am, J. Obstet. Gynecol. 2017,216(5),459-476.e10. http:\/\/dx.doi.org\/10.1016\/j.ajog.2016.11.1033 PMID: 27871836","journal-title":"Am, J.Obstet.Gynecol"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.ygyno.2006.06.027","volume":"103(3)","author":"Marnitz,S.","year":"2006","unstructured":"Marnitz,S.; K\u00f6hler,C.; M\u00fcller,M.; Behrens,K.; Hasenbein,K.; Schneider, A. Indications for primary and secondary exenterations in patients with cervical cancer. Gynecol. Oncol. 2006,103(3),1023-1030. http:\/\/dx.doi.org\/10.1016\/j.ygyno.2006.06.027 PMID: 16890276","journal-title":"Gynecol.Oncol"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1245\/s10434-008-9841-1","volume":"15(5)","author":"Ballester,M.","year":"2008","unstructured":"Ballester,M.; Dubernard,G.; Rouzier,R.; Barranger,E.; Darai, E. Use of the sentinel node procedure to stage endometrial cancer. Ann. Surg. Oncol. 2008,15(5),1523-1529. http:\/\/dx.doi.org\/10.1245\/s10434-008-9841-1 PMID: 18322758","journal-title":"Ann.Surg.Oncol"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"183","DOI":"10.332 2\/caac.20113","volume":"61(3)","author":"Jelovac,D.","year":"2011","unstructured":"Jelovac,D.; Armstrong, D.K. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J. Clin. 2011,61(3),183-203. http:\/\/dx.doi.org\/10.332 2\/caac.20113 PMID: 21521830","journal-title":"CA Cancer J.Clin"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"4973","DOI":"10.1002\/cncr.25498","volume":"116(21)","author":"Brown,J.","year":"2010","unstructured":"Brown,J.; Smith, J.A.; Ramondetta, L.M.; Sood, A.K.; Ramirez, P.T.; Coleman, R.L.; Levenback, C.F.; Munsell, M.F.; Jung,M.; Wolf, J.K. Combination of gemcitabine and cisplatin is highly active in women with endometrial carcinoma: results of a prospective phase 2 trial. Cancer. 2010,116(21),4973-4979. http:\/\/dx.doi.org\/10.1002\/cncr.25498 PMID: 20665499","journal-title":"Cancer"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1200\/JCO.2007.12.1939","volume":"26(1)","author":"Garcia, A.A.","year":"2008","unstructured":"Garcia, A.A.; Hirte,H.; Fleming,G.; Yang,D.; Tsao-Wei, D.D.; Roman,L.; Groshen,S.; Swenson,S.; Markland,F.; Gandara,D.; Scudder,S.; Morgan,R.; Chen,H.; Lenz, H.J.; Oza, A.M. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia, J. Clin. Oncol. 2008,26(1),76-82. http:\/\/dx.doi.org\/10.1200\/JCO.2007.12.1939 PMID: 18165643","journal-title":"Clin.Oncol"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1111\/j.1525-1438.2007.01094.x","volume":"18(4)","author":"Sorbe,B.","year":"2008","unstructured":"Sorbe,B.; Andersson,H.; Boman,K.; Rosenberg,P.; Kalling, M. Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel-long-term follow-up. Int, J. Gynecol. Cancer. 2008,18(4),803-808. http:\/\/dx.doi.org\/10.1111\/j.1525-1438.2007.01094.x PMID: 17944917","journal-title":"Int, J.Gynecol.Cancer"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"iv72","DOI":"10.1093\/annonc\/mdx220","volume":"28(4 suppl-4)","author":"Marth,C.","year":"2017","unstructured":"Marth,C.; Landoni,F.; Mahner,S.; McCormack,M.; Gonzalez-Martin,A.; Colombo, N. ESMO Guidelines Committee. Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2017,28(4 suppl-4),iv72-iv83. http:\/\/dx.doi.org\/10.1093\/annonc\/mdx220 PMID: 28881916","journal-title":"Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Ann.Oncol"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1056\/NEJMoa052985","volume":"354(1)","author":"Armstrong, D.K.","year":"2006","unstructured":"Armstrong, D.K.; Bundy,B.; Wenzel,L.; Huang, H.Q.; Baergen,R.; Lele,S.; Copeland, L.J.; Walker, J.L.; Burger, R.A. Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer, N. Engl, J. Med. 2006,354(1),34-43. http:\/\/dx.doi.org\/10.1056\/NEJMoa052985 PMID: 16394300","journal-title":"N.Engl, J.Med"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1016\/S0140-6736(09) 61157-0","volume":"374(9698)","author":"Katsumata,N.","year":"2009","unstructured":"Katsumata,N.; Yasuda,M.; Takahashi,F.; Isonishi,S.; Jobo,T.; Aoki,D.; Tsuda,H.; Sugiyama,T.; Kodama,S.; Kimura,E.; Ochiai,K.; Noda, K. Japanese Gynecologic Oncology Group. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009,374(9698),1331-1338. http:\/\/dx.doi.org\/10.1016\/S0140-6736(09) 61157-0 PMID: 19767092","journal-title":"Dose-dense paclitaxel onceaweek in combination with carboplatin every 3 weeks for advanced ovarian cancer:aphase 3, open-label, randomised controlled trial.Lancet"},{"key":"ref=127","first-page":"459","volume":"4(6)","author":"Obel, J.C.","year":"2006","unstructured":"Obel, J.C.; Friberg,G.; Fleming, G.F. Chemotherapy in endometrial cancer. Clin. Adv. Hematol. Oncol. 2006,4(6),459-468. PMID: 16981669","journal-title":"Clin.Adv..Hematol.Oncol"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1001\/jama.1947.02890070014004","volume":"135(7)","author":"Heyman,J","year":"1947","unstructured":"Heyman.; J. Improvement of results in the treatment of uterine cancer, J. Am. Med. Assoc. 1947,135(7),412-416. http:\/\/dx.doi.org\/10.1001\/jama.1947.02890070014004 PMID: 20264945","journal-title":"Am.Med.Assoc"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/BF02858792","volume":"39","author":"Farnsworth, N.R.","year":"1985","unstructured":"Farnsworth, N.R.; Soejarto, D.D. Potential consequence of plant extinction in United States on the current and future availability of prescription drugs. Econ. Bot. 1985,39,231-240. http:\/\/dx.doi.org\/10.1007\/BF02858792","journal-title":"Econ.Bot"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1021\/np200391c","volume":"74(6)","author":"Kinghorn, A.D.","year":"2011","unstructured":"Kinghorn, A.D.; Pan,L.; Fletcher, J.N.; Chai, H. The relevance of higher plants in lead compound discovery programs, J. Nat. Prod. 2011,74(6),1539-1555. http:\/\/dx.doi.org\/10.1021\/np200391c PMID: 21650152","journal-title":"Nat.Prod"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"5274","DOI":"10.1016\/j.bmc.2005.05.067","volume":"13(17)","author":"Tulp,M.","year":"2005","unstructured":"Tulp,M.; Bohlin, L. Rediscovery of known natural compounds: nuisance or goldmine? Bioorg. Med. Chem. 2005,13(17),5274-5282. http:\/\/dx.doi.org\/10.1016\/j.bmc.2005.05.067 PMID: 16019216","journal-title":"Med.Chem"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1021\/np9604893","volume":"60(1)","author":"Cragg, G.M.","year":"1997","unstructured":"Cragg, G.M.; Newman, D.J.; Snader, K.M. Natural products in drug discovery and development, J. Nat. Prod. 1997,60(1),52-60. http:\/\/dx.doi.org\/10.1021\/np9604893 PMID: 9014353","journal-title":"Nat.Prod"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"3012","DOI":"10.1021\/cr900019j","volume":"109(7)","author":"Cragg, G.M.","year":"2009","unstructured":"Cragg, G.M.; Grothaus, P.G.; Newman, D.J. Impact of natural products on developing new anti-cancer agents. Chem. Rev. 2009,109(7),3012-3043. http:\/\/dx.doi.org\/10.1021\/cr900019j PMID: 19422222","journal-title":"Chem.Rev"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1021\/np068054v","volume":"70(3)","author":"Newman, D.J.","year":"2007","unstructured":"Newman, D.J.; Cragg, G.M. Natural products as sources of new drugs over the last 25 years, J. Nat. Prod. 2007,70(3),461-477. http:\/\/dx.doi.org\/10.1021\/np068054v PMID: 17309302","journal-title":"Nat.Prod"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1021\/np200906s","volume":"75(3)","author":"Newman, D.J.","year":"2012","unstructured":"Newman, D.J.; Cragg, G.M. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J. Nat. Prod. 2012,75(3),311-335. http:\/\/dx.doi.org\/10.1021\/np200906s PMID: 22316239","journal-title":"J.Nat.Prod"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/fcp.12117","volume":"29(3)","author":"Etienne-Grimaldi, M.C.","year":"2015","unstructured":"Etienne-Grimaldi, M.C.; Boyer, J.C.; Thomas,F.; Quaranta,S.; Picard,N.; Loriot, M.A.; Narjoz,C.; Poncet,D.; Gagnieu, M.C.; Ged,C.; Broly,F.; Le Morvan,V.; Bouqui\u00e9, R.; Gaub, M.P.; Philibert,L.; Ghiri-nghelli,F.; Le Guellec, C. Collective work by Groupe de Pharmacologie Clinique Oncologique (GPCO-Unicancer) ; French R\u00e9seau National de Pharmacog\u00e9n\u00e9tique Hospitali\u00e8re (RNPGx) . UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice. Fundam. Clin. Pharmacol. 2015,29(3),219-237. http:\/\/dx.doi.org\/10.1111\/fcp.12117 PMID: 25817555","journal-title":"Fundam.Clin.Pharmacol"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"4649","DOI":"10.1200\/JCO.2009.21.8909","volume":"27(28)","author":"Monk, B.J.","year":"2009","unstructured":"Monk, B.J.; Sill, M.W.; McMeekin, D.S.; Cohn, D.E.; Ramondetta, L.M.; Boardman, C.H.; Benda,J.; Cella, D. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study, J. Clin. Oncol. 2009,27(28),4649-4655. http:\/\/dx.doi.org\/10.1200\/JCO.2009.21.8909 PMID: 19720909","journal-title":"Clin.Oncol"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1016\/j.bmc.2003.11.036","volume":"12(7)","author":"Thomas, C.J.","year":"2004","unstructured":"Thomas, C.J.; Rahier, N.J.; Hecht, S.M. Camptothecin: current per spectives. Bioorg. Med. Chem. 2004,12(7),1585-1604. http:\/\/dx.doi.org\/10.1016\/j.bmc.2003.11.036 PMID: 15028252","journal-title":"Bioorg.Med.Chem"},{"key":"ref=139","first-page":"103","volume":"56(1)","author":"Gottlieb, J.A.","year":"1972","unstructured":"Gottlieb, J.A.; Luce, J.K. Treatment of malignant melanoma with camptothecin (NSC-100880) . Cancer Chemother. Rep. 1972,56(1),103-105. PMID: 5030802","journal-title":"Cancer Chemother.Rep"},{"key":"ref=140","first-page":"515","volume":"56(4)","author":"Muggia, F.M.","year":"1972","unstructured":"Muggia, F.M.; Creaven, P.J.; Hansen, H.H.; Cohen, M.H.; Selawry, O.S. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Cancer Chemother. Rep. 1972,56(4),515-521. PMID: 5081595","journal-title":"Cancer Chemother.Rep"},{"key":"ref=141","first-page":"649","volume":"56(5)","author":"Moertel, C.G.","year":"1972","unstructured":"Moertel, C.G.; Schutt, A.J.; Reitemeier, R.J.; Hahn, R.G. Phase II study of 5-azacytidine (NSC-102816)  in the treatment of advanced gastrointestinal cancer. Cancer Chemother. Rep. 1972,56(5),649-652. PMID: 4119908","journal-title":"Cancer Chemother.Rep"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"3888","DOI":"10.1021\/ja00968a057","volume":"88(16)","author":"Wall, M.E.","year":"1966","unstructured":"Wall, M.E.; Wani, M.C.; Cook, C.E.; Palmer, K.H.; McPhail, A.T.; Sim, G.A. Plant antitumor agents, I. Isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata, J. Am. Chem. Soc. 1966,88(16),3888-3890. http:\/\/dx.doi.org\/10.1021\/ja00968a057","journal-title":"J.Am.Chem.Soc"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1021\/np030498t","volume":"67(2)","author":"Oberlies, N.H.","year":"2004","unstructured":"Oberlies, N.H.; Kroll, D.J. Camptothecin and taxol: historic achievements in natural products research, J. Nat. Prod. 2004,67(2),129-135. http:\/\/dx.doi.org\/10.1021\/np030498t PMID: 14987046","journal-title":"Nat.Prod"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1021\/ja00738a045","volume":"93(9)","author":"Wani, M.C.","year":"1971","unstructured":"Wani, M.C.; Taylor, H.L.; Wall, M.E.; Coggon,P.; McPhail, A.T. Plant antitumor agents. VI. The isolation and structure of taxol, a novel an tileukemic and antitumor agent from Taxus brevifolia, J. Am. Chem. Soc. 1971,93(9),2325-2327. http:\/\/dx.doi.org\/10.1021\/ja00738a045 PMID: 5553076","journal-title":"J.Am.Chem.Soc"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1159\/000320579","volume":"78(5-6)","author":"Abaid, L.N.","year":"2010","unstructured":"Abaid, L.N.; Goldstein, B.H.; Micha, J.P.; Rettenmaier, M.A.; Brown, J.V. III.; Markman, M. Improved overall survival with 12 cycles of single-agent paclitaxel maintenance therapy following a complete response to induction chemotherapy in advanced ovarian carcinoma. Oncology. 2010,78(5-6),389-393. http:\/\/dx.doi.org\/10.1159\/000320579 PMID: 20798562","journal-title":"Oncology"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1006\/jmbi.2001.5077","volume":"313(5)","author":"Lwe,J.","year":"2001","unstructured":"L\u00f6we,J.; Li,H.; Downing, K.H.; Nogales, E. Refined structure of alpha beta-tubulin at 3.5 A resolution, J. Mol. Biol. 2001,313(5),1045-1057. http:\/\/dx.doi.org\/10.1006\/jmbi.2001.5077 PMID: 11700061","journal-title":"Mol.Biol"},{"key":"ref=147","first-page":"S19","volume":"24(19)","author":"R,owinsky.","year":"1997","unstructured":"R,owinsky.; E.K. Paclitaxel pharmacology and other tumor types. Semin. Oncol. 1997,24(19),S19-1-S19-12","journal-title":"Semin..Oncol"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1517\/14656566.3.6.755","volume":"3 (6)","author":"Mekhail, T.M.","year":"2002","unstructured":"Mekhail, T.M.; Markman, M. Paclitaxel in cancer therapy. Expert Opin. Pharmacother. 2002,3 (6),755-766. http:\/\/dx.doi.org\/10.1517\/14656566.3.6.755 PMID: 12036415","journal-title":"Expert Opin.Pharmacother"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"3559","DOI":"10.1021\/acs.jafc.5b00448","volume":"63(13)","author":"Chen, F.P.","year":"2015","unstructured":"Chen, F.P.; Li, B.S.; Tang, C.H. Nanocomplexation between curcumin and soy protein isolate: influence on curcumin stability\/bioaccessibility and in vitro protein digestibility, J. Agric. Food Chem. 2015,63(13),3559-3569. http:\/\/dx.doi.org\/10.1021\/acs.jafc.5b00448 PMID: 25779681","journal-title":"Agric.Food Chem"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1517\/13543784.2011.576666","volume":"20(6)","author":"Galic, V.L.","year":"2011","unstructured":"Galic, V.L.; Wright, J.D.; Lewin, S.N.; Herzog, T.J. Paclitaxel poliglumex for ovarian cancer. Expert Opin. Investig. Drugs. 2011,20(6),813-821. http:\/\/dx.doi.org\/10.1517\/13543784.2011.576666 PMID: 21470062","journal-title":"Expert Opin.Investig.Drugs"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.ctrv.2007.07.013","volume":"33(8)","author":"Stordal,B.","year":"2007","unstructured":"Stordal,B.; Pavlakis,N.; Davey, R. A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship. Cancer Treat. Rev. 2007,33(8),688-703. http:\/\/dx.doi.org\/10.1016\/j.ctrv.2007.07.013 PMID: 17881133","journal-title":"Cancer Treat.Rev"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/S0223-5234(00) 00176-8","volume":"35(7-8)","author":"Gordaliza,M.","year":"2000","unstructured":"Gordaliza,M.; Castro, M.A.; Miguel-del Corral, J.M.; L\u00f3pez-V\u00e1zquez, M.L.; A Garc\u00eda,P.; Garc\u00eda-Gr\u00e1valos, M.D.; San Feliciano, A. Synthesis and antineoplastic activity of cyclolignan aldehydes. Eur, J. Med. Chem. 2000,35(7-8),691-698. http:\/\/dx.doi.org\/10.1016\/S0223-5234(00) 00176-8 PMID: 10960184","journal-title":"Eur, J.Med.Chem"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1097\/CAD.0b013e32834ea5d0","volume":"23(3)","author":"Hwang, J.H.","year":"2012","unstructured":"Hwang, J.H.; Yoo, H.J.; Lim, M.C.; Seo, S.S.; Park, S.Y.; Kang, S. Phase I clinical trial of alternating belotecan and oral etoposide in patients with platinum-resistant or heavily treated ovarian cancer. Anticancer Drugs. 2012,23(3),321-325. http:\/\/dx.doi.org\/10.1097\/CAD.0b013e32834ea5d0 PMID: 22156765","journal-title":"Anticancer Drugs"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1177\/1758834015584763","volume":"7(4)","author":"Vergote,I.","year":"2015","unstructured":"Vergote,I.; Leamon, C.P. Vintafolide: a novel targeted therapy for the treatment of folate receptor expressing tumors. Ther. Adv. Med. Oncol. 2015,7(4),206-218. http:\/\/dx.doi.org\/10.1177\/1758834015584763 PMID: 26136852","journal-title":"Ther.Adv.Med.Oncol"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s11912-006-0044-2","volume":"8(2)","author":"Choueiri, T.K.","year":"2006","unstructured":"Choueiri, T.K.; Wesolowski,R.; Mekhail, T.M. Phenoxodiol: isoflavone analog with antineoplastic activity. Curr. Oncol. Rep. 2006,8(2),104-107. http:\/\/dx.doi.org\/10.1007\/s11912-006-0044-2 PMID: 16507219","journal-title":"Curr.Oncol.Rep"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1097\/IGC.0b013e3182126f05","volume":"21(4)","author":"Kelly, M.G.","year":"2011","unstructured":"Kelly, M.G.; Mor,G.; Husband,A.; O\u2019Malley, D.M.; Baker,L.; Azodi,M.; Schwartz, P.E.; Rutherford, T.J. Phase II evaluation of phenoxodiol in combination with cisplatin or paclitaxel in women with platinum\/taxane-refractory\/resistant epithelial ovarian, fallopian tube, or primary peritoneal cancers. Int, J. Gynecol. Cancer. 2011,21(4),633-639. http:\/\/dx.doi.org\/10.1097\/IGC.0b013e3182126f05 PMID: 21412168","journal-title":"Int, J.Gynecol.Cancer"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1016\/S0960-894X(98) 00579-4","volume":"8(22)","author":"Ohsumi,K.","year":"1998","unstructured":"Ohsumi,K.; Hatanaka,T.; Fujita,K.; Nakagawa,R.; F ukuda,Y.; Nihei,Y.; Suga,Y.; Morinaga,Y.; Akiyama,Y.; Tsuji, T. Syntheses and antitumor activity of cis-restricted combretastatins: 5-membered heterocyclic analogues. Bioorg. Med. Chem. Lett. 1998,8(22),3153-3158. http:\/\/dx.doi.org\/10.1016\/S0960-894X(98) 00579-4 PMID: 9873694","journal-title":"Bioorg.Med.Chem.Lett"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1021\/jm00010a011","volume":"38(10)","author":"Pettit, G.R.","year":"1995","unstructured":"Pettit, G.R.; Si-ngh, S.B.; Boyd, M.R.; Hamel,E.; Pettit, R.K.; Schmidt, J.M.; Hogan, F. Antineoplastic agents. 291. Isolation and synthesis of combretastatins A-4, A-5, and A-6(1a) . J. Med. Chem. 1995,38(10),1666-1672. http:\/\/dx.doi.org\/10.1021\/jm00010a011 PMID: 7752190","journal-title":"291.Isolation and synthesis of combretastatins A-4, A-5, and A-6(1a) .J.Med.Chem"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/S0140-6736(10) 61268-8","volume":"376(9747)","author":"Rustin, G.J.","year":"2010","unstructured":"Rustin, G.J.; van der Burg, M.E.; Griffin, C.L.; Guthrie,D.; Lamont,A.; Jayson, G.C.; Kristensen,G.; Mediola,C.; Coens,C.; Qian,W.; Parmar, M.K.; Swart, A.M. MRC OV05; EORTC 55955 investigators. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05\/EORTC 55955): a randomised trial. Lancet. 2010,376(9747),1155-1163. http:\/\/dx.doi.org\/10.1016\/S0140-6736(10) 61268-8 PMID: 20888993","journal-title":"Lancet"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1093\/annonc\/mdq708","volume":"22(9)","author":"Zweifel,M.","year":"2011","unstructured":"Zweifel,M.; Jayson, G.C.; Reed, N.S.; Osborne,R.; Hassan,B.; Ledermann,J.; Shreeves,G.; Poupard,L.; Lu, S.P.; Balkissoon,J.; Chaplin, D.J.; Rustin, G.J. Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer. Ann. Oncol. 2011,22(9),2036-2041. http:\/\/dx.doi.org\/10.1093\/annonc\/mdq708 PMID: 21273348","journal-title":"Ann.Oncol"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s00280-003-0599-7","volume":"51(6)","author":"Azzoli, C.G.","year":"2003","unstructured":"Azzoli, C.G.; Miller, V.A.; Ng, K.K.; Krug, L.M.; Spriggs, D.R.; Tong, W.P.; Riedel, E.R.; Kris, M.G. A phase I trial of per illyl alcohol in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 2003,51(6),493-498. http:\/\/dx.doi.org\/10.1007\/s00280-003-0599-7 PMID: 12695855","journal-title":"Cancer Chemother.Pharmacol"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1006\/gyno.2002.6647","volume":"85(3)","author":"Bailey, H.H.","year":"2002","unstructured":"Bailey, H.H.; Levy,D.; Harris, L.S.; Schink, J.C.; Foss,F.; Beatty,P.; Wadler, S. A phase II trial of daily perillyl alcohol in patients with advanced ovarian cancer: Eastern Cooperative Oncology G roup Study E2E96. Gynecol. Oncol. 2002,85(3),464-468. http:\/\/dx.doi.org\/10.1006\/gyno.2002.6647 PMID: 12051875","journal-title":"Gynecol.Oncol"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"R1071","DOI":"10.1152\/ajpregu.90925.2008","volume":"296(4)","author":"Davis, J.M.","year":"2009","unstructured":"Davis, J.M.; Murphy, E.A.; Carmichael, M.D.; Davis, B. Quercetin increases brain and muscle mitochondrial biogenesis and exercise tolerance. Am, J. Physiol. Regul. Integr. Comp. Physiol. 2009,296(4),R1071-R1077. http:\/\/dx.doi.org\/10.1152\/ajpregu.90925.2008 PMID: 19211721","journal-title":"Am, J.Physiol.Regul.Integr.Comp.Physiol"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/bjc.1990.414","volume":"62(1)","author":"Scambia,G.","year":"1990","unstructured":"Scambia,G.; Ranelletti, F.O.; Panici, P.B.; Piantelli,M.; Bonanno,G.; Vincenzo,R.; Ferrandina,G.; Rumi,C.; Larocca, L.M.; Mancuso, S. Inhibitory effect of quercetin on OVA 433 cells and presence oftype II oestrogen binding sites in primary ovarian tumors and cultured cells. Br, J. Cancer. 1990,62(1),942-946. http:\/\/dx.doi.org\/10.1038\/bjc.1990.414 PMID: 2167724","journal-title":"Br, J.Cancer"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"7021","DOI":"10.1039\/c2nr32181e","volume":"4(22)","author":"Gao,X.","year":"2012","unstructured":"Gao,X.; Wang,B.; Wei,X.; Men,K.; Zheng,F.; Zhou,Y.; Zheng,Y.; Gou,M.; Huang,M.; Guo,G.; Huang,N.; Qian,Z.; Wei, Y. Anticancer effect and mechanism of polymer micelle-encapsulated quercetin on ovarian cancer. Nanoscale. 2012,4(22),7021-7030. http:\/\/dx.doi.org\/10.1039\/c2nr32181e PMID: 23044718","journal-title":"Nanoscale"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"590","DOI":"10.17772\/gp\/1609","volume":"84(7)","author":"Maciejczyk,A.","year":"2013","unstructured":"Maciejczyk,A.; Surowiak, P. Quercetin inhibits proliferation and increases sensitivity of ovarian cancer cells to cisplatin and paclitaxel. Ginekol. Pol. 2013,84(7),590-595. http:\/\/dx.doi.org\/10.17772\/gp\/1609 PMID: 24032269","journal-title":"Ginekol.Pol"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1089\/107555302320825075","volume":"8(5)","author":"Ye,F.","year":"2002","unstructured":"Ye,F.; Xui,L.; Yi,J.; Zhang,W.; Zhang, D.Y. Anticancer activity of Scutellaria baicalensis and its potential mechanism, J. Altern. Complement. Med. 2002,8(5),567-572. http:\/\/dx.doi.org\/10.1089\/107555302320825075 PMID: 12470437","journal-title":"Altern.Complement.Med"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.ccell.2015.09.006","volume":"28(4)","author":"Yan,X.","year":"2015","unstructured":"Yan,X.; Hu,Z.; Feng,Y.; Hu,X.; Yuan,J.; Zhao, S.D.; Zhang,Y.; Yang,L.; Shan,W.; He,Q.; Fan,L.; Kandalaft, L.E.; Tanyi, J.L.; Li,C.; Yuan, C.X.; Zhang,D.; Yuan,H.; Hua,K.; Lu,Y.; Katsaros,D.; Huang,Q.; Montone,K.; Fan,Y.; Coukos,G.; Boyd,J.; Sood, A.K.; Rebbeck,T.; Mills, G.B.; Dang, C.V.; Zhang, L. Comprehensive genomic characterization of long non-coding rnas across human cancers. Cancer Cell. 2015,28(4),529-540. http:\/\/dx.doi.org\/10.1016\/j.ccell.2015.09.006 PMID: 26461095","journal-title":"Cancer Cell"},{"key":"ref=169","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1055\/s-0028-1100266","volume":"11","author":"El-Dakhakhany.","year":"1963","unstructured":"El-Dakhakhany.; M. Studies on the chemical constitution of Egyptian N. sativa L. seeds. Planta Med. 1963,11,465-470. http:\/\/dx.doi.org\/10.1055\/s-0028-1100266","journal-title":"sativa L.seeds.Planta Med"},{"key":"ref=170","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.biocel.2005.10.009","volume":"38 (8)","author":"Gali-Muhtasib,H.","year":"2006","unstructured":"Gali-Muhtasib,H.; Roessner,A.; Schneider-Stock, R. Thymoquinone: a promising anti-cancer drug from natural sources. Int, J. Biochem. Cell Biol. 2006,38 (8),1249-1253. ht tp:\/\/dx.doi.org\/10.1016\/j.biocel.2005.10.009 PMID: 16314136","journal-title":"Int, J.Biochem.Cell Biol"},{"key":"ref=171","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.bcp.2011.09.029","volume":"83(4)","author":"Woo, C.C.","year":"2012","unstructured":"Woo, C.C.; Kumar, A.P.; Sethi,G.; Tan, K.H. Thymoquinone: potential cure for inflammatory disorders and cancer. Biochem. Pharmacol. 2012,83(4),443-451. http:\/\/dx.doi.org\/10.1016\/j.bcp.2011.09.029 PMID: 22005518","journal-title":"Biochem.Pharmacol"},{"key":"ref=172","doi-asserted-by":"publisher","first-page":"46.","DOI":"10.1186\/s13048-015-0177-8","volume":"8","author":"Wilson, A.J.","year":"2015","unstructured":"Wilson, A.J.; Saskowski,J.; Barham,W.; Yull,F.; Khabele, D. Thymoquinone enhances cisplatin-response through direct tumor effects in a syngeneic mouse model of ovarian cancer, J. Ovarian Res. 2015,8,46. http:\/\/dx.doi.org\/10.1186\/s13048-015-0177-8 PMID: 26215403","journal-title":"Ovarian Res"},{"key":"ref=173","first-page":"3789","volume":"31(11)","author":"Nessa, M.U.","year":"2011","unstructured":"Nessa, M.U.; Beale,P.; Chan,C.; Yu, J.Q.; Huq, F. Synergism from combinations of cisplatin and oxaliplatin with quercetin and thymoquinone in human ovarian tumour models. Anticancer Res. 2011,31(11),3789-3797. PMID: 22110201","journal-title":"Anticancer Res"},{"key":"ref=174","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1002\/med.10053","volume":"24(1)","author":"Cichewicz, R.H.","year":"2004","unstructured":"Cichewicz, R.H.; Kouzi, S.A. Chemistry, biological activity, and chemotherapeutic potential of betulinic acid for the prevention and treatment of cancer and HIV infection. Med. Res. Rev. 2004,24(1),90-114. http:\/\/dx.doi.org\/10.1002\/med.10053 PMID: 14595673","journal-title":"Med.Res.Rev"},{"key":"ref=175","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.3390\/ijms 9061096","volume":"9(6)","author":"Fulda,S","year":"2008","unstructured":"Fulda.; S. Betulinic Acid for cancer treatment and prevention. Int, J. Mol. Sci. 2008,9(6),1096-1107. http:\/\/dx.doi.org\/10.3390\/ijms 9061096 PMID: 19325847","journal-title":"Int, J.Mol.Sci"},{"key":"ref=176","first-page":"252","volume":"8(1)","author":"Wang, Y.J.","year":"2015","unstructured":"Wang, Y.J.; Liu, J.B.; Dou, Y.C. Sequential treatment with betulinic acid followed by 5-fluorouracil shows synergistic cytotoxic activity in ovarian cancer cells. Int, J. Clin. Exp. Pathol. 2015,8(1),252-259. PMID: 25755712","journal-title":"Int, J.Clin..Exp.Pathol"},{"key":"ref=177","first-page":"1102","volume":"23(12)","author":"Chen,Y.J","year":"2002","unstructured":"Chen.; Y.J. Potential role of tetrandrine in cancer therapy. Acta Pharmacol. Sin. 2002,23(12),1102-1106. PMID: 12466047","journal-title":"Acta Pharmacol.Sin"},{"key":"ref=178","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1097\/00001813-199803000-00008","volume":"9(3)","author":"Choi, S.U.","year":"1998","unstructured":"Choi, S.U.; Park, S.H.; Kim, K.H.; Choi, E.J.; Kim,S.; Park, W.K.; Zhang, Y.H.; Kim, H.S.; Jung, N.P.; Lee, C.O. The bisbenzylisoquinoline alkaloids, tetrandine and fangchinoline, enhance the cytotoxicity of multidrug resistance-related drugs via modulation of P-glycoprotein. Anticancer Drugs. 1998,9(3),255-261. http:\/\/dx.doi.org\/10.1097\/00001813-199803000-00008 PMID: 9625436","journal-title":"Anticancer Drugs"},{"key":"ref=179","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.canlet.2011.01.022","volume":"304(1)","author":"Zhang,Y.","year":"2011","unstructured":"Zhang,Y.; Wang,C.; Wang,H.; Wang,K.; Du,Y.; Zhang, J. Combination of Tetrandrine with cisplatin enhances cytotoxicity through growth suppression and apoptosis in ovarian cancer in v itro and in vivo. Cancer Lett. 2011,304(1),21-32. http:\/\/dx.doi.org\/10.1016\/j.canlet.2011.01.022 PMID: 21333438","journal-title":"Cancer Lett"},{"key":"ref=180","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/j.phymed.2014.04.029","volume":"21(8-9)","author":"Sun, Y.F.","year":"2014","unstructured":"Sun, Y.F.; Wink, M. Tetrandrine and fangchinoline, bisbenzylisoquinoline alkaloids from Stephania tetrandra can reverse multidrug resistance by inhibiting P-glycoprotein activity in multidrug resistant human cancer cells. Phytomedicine. 2014,21(8-9),1110-1119. http:\/\/dx.doi.org\/10.1016\/j.phymed.2014.04.029 PMID: 24856768","journal-title":"Phytomedicine"},{"key":"ref=181","doi-asserted-by":"publisher","first-page":"174.","DOI":"10.3390\/biom9050174","volume":"9(5)","author":"Kashyap,D.","year":"2019","unstructured":"Kashyap,D.; Garg, V.K.; Tuli, H.S.; Yerer, M.B.; Sak,K.; Sharma, A.K.; Kumar,M.; Aggarwal,V.; Sandhu, S.S. Fisetin and quercetin: Promising flavonoids with chemopreventive potential. Biomolecules. 2019,9(5),174. http:\/\/dx.doi.org\/10.3390\/biom9050174 PMID: 31064104","journal-title":"Biomolecules"},{"key":"ref=182","doi-asserted-by":"publisher","first-page":"1273.","DOI":"10.1038\/2121273a0","volume":"212(5067)","author":"G\u00e1bor,M.","year":"1966","unstructured":"G\u00e1bor,M.; Eperjessy, E. Antibacterial effect of fisetin and fisetinidin. Nature. 1966,212(5067),1273. http:\/\/dx.doi.org\/10.1038\/2121273a0 PMID: 21090477","journal-title":"Nature"},{"key":"ref=183","doi-asserted-by":"publisher","first-page":"e71983.","DOI":"10.1371\/journal.pone.0071983","volume":"8(8)","author":"Chou, R.H.","year":"2013","unstructured":"Chou, R.H.; Hsieh, S.C.; Yu, Y.L.; Huang, M.H.; Huang, Y.C.; Hsieh, Y.H. Fisetin inhibits migration and invasion of human cervical cancer cells by down-regulating urokinase plasminogen activator expression through suppressing the p38 MAPK-dependent NF-?B signaling pathway. PLoS One. 2013,8(8),e71983. http:\/\/dx.doi.org\/10.1371\/journal.pone.0071983 PMID: 23940799","journal-title":"PLoS One"},{"key":"ref=184","doi-asserted-by":"publisher","first-page":"7.","DOI":"10.1055\/s-0034-1382585","volume":"80","author":"Uche,F.","year":"2014","unstructured":"Uche,F.; Li, W.W.; Richardson,A.; Greenhough, T.J. Anti-ovarian cancer activities of alkaloids from Triclisia subcordata olive (Menispermecaea) . Planta Med. 2014,80,7. http:\/\/dx.doi.org\/10.1055\/s-0034-1382585","journal-title":"Planta Med"},{"key":"ref=185","first-page":"53","volume":"21(3)","author":"Sahin,F.","year":"2004","unstructured":"Sahin,F.; Avcu,F.; Saydam, G. Red grape seed extract and its main components resveratrol and borax show cytotoxic effect on malignant cell lines. Turk, J. Haematol. 2004,21(3),53-54","journal-title":"Turk, J..Haematol"},{"key":"ref=186","doi-asserted-by":"publisher","first-page":"282","DOI":"10.2164\/jandrol.106.000968","volume":"28(2)","author":"Benitez, D.A.","year":"2007","unstructured":"Benitez, D.A.; Pozo-Guisado,E.; Alvarez-Barrientos,A.; Fernandez-Salguero, P.M.; Castell\u00f3n, E.A. Mechanisms involved in resveratrol-induced apoptosis and cell cycle arrest in prostate cancer-derived cell lines, J. Androl. 2007,28(2),282-293. http:\/\/dx.doi.org\/10.2164\/jandrol.106.000968 PMID: 17050787","journal-title":"Androl"},{"key":"ref=187","doi-asserted-by":"publisher","first-page":"5628","DOI":"10.3748\/wjg.v12.i35.5628","volume":"12(35)","author":"Riles, W.L.","year":"2006","unstructured":"Riles, W.L.; Erickson,J.; Nayyar,S.; Atten, M.J.; Attar, B.M.; Holian, O. Resveratrol engages selective apoptotic signals in gastric adenocarcinoma cells. World J. Gastroenterol. 2006,12(35),5628-5634. http:\/\/dx.doi.org\/10.3748\/wjg.v12.i35.5628 PMID: 17007014","journal-title":"World J.Gastroenterol"},{"key":"ref=188","first-page":"88","volume":"40","author":"Ayla,S.","year":"2009","unstructured":"Ayla,S.; \u00d6ktem,G.; Bilir, A. MDAH-2774 Investigation of different drug effects with nitric oxide synthase changes in human ovarian cancer three-dimensional cell culture. Cerrahpasa Med J. 2009,40,88-96","journal-title":"Cerrahpasa Med J"},{"key":"ref=189","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1093\/carcin\/17.2.277","volume":"17(2)","author":"Barcelo,S.","year":"1996","unstructured":"Barcelo,S.; Gardiner, J.M.; Gescher,A.; Chipman, J.K. CYP2E1-mediated mechanism of anti-genotoxicity of the broccoli constituent sulforaphane. Carcinogenesis. 1996,17(2),277-282. http:\/\/dx.doi.org\/10.1093\/carcin\/17.2.277 PMID: 8625450","journal-title":"Carcinogenesis"},{"key":"ref=190","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1158\/1535-7163.MCT-06-0404","volume":"6(1)","author":"Chaudhuri,D.","year":"2007","unstructured":"Chaudhuri,D.; Orsulic,S.; Ashok, B.T. Antiproliferative activity of sulforaphane in Akt-overexpressing ovarian cancer cells. Mol. Cancer Ther. 2007,6(1),334-345. http:\/\/dx.doi.org\/10.1158\/1535-7163.MCT-06-0404 PMID: 17237292","journal-title":"Mol.Cancer Ther"},{"key":"ref=191","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.mrrev.2006.10.004","volume":"635(2-3)","author":"Fimognari,C.","year":"2007","unstructured":"Fimognari,C.; Hrelia, P. Sulforaphane as a promising molecule for fighting cancer. M utat. Res. 2007,635(2-3),90-104. http:\/\/dx.doi.org\/10.1016\/j.mrrev.2006.10.004 PMID: 17134937","journal-title":"Mutat.Res"},{"key":"ref=192","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s12263-011-0209-y","volume":"6(2)","author":"Kim, M.K.","year":"2011","unstructured":"Kim, M.K.; Kim,K.; Han, J.Y.; Lim, J.M.; Song, Y.S. Modulation of inflammatory signaling pathways by phytochemicals in ovarian cancer. Genes Nutr. 2011,6(2),109-115. http:\/\/dx.doi.org\/10.1007\/s12263-011-0209-y PMID: 21484164","journal-title":"Genes Nutr"},{"key":"ref=193","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1002\/1097-4644(20001215) 79:4<594::AID-JCB80>3.0.CO.;-4","volume":"79(4)","author":"Cappelletti,V.","year":"2000","unstructured":"Cappelletti,V.; Fioravanti,L.; Miodini,P.; Di Fronzo, G. Genistein blocks breast cancer cells in the G(2) M phase of the cell cycle, J. Cell. Biochem. 2000,79(4),594-600. http:\/\/dx.doi.org\/10.1002\/1097-4644(20001215) 79:4<594::AID-JCB80>3.0.CO.;-4 PMID: 10996850","journal-title":"Cell.Biochem"},{"key":"ref=194","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1021\/np060609z","volume":"70(5)","author":"L\u00f3pez-Lazaro,M.","year":"2007","unstructured":"L\u00f3pez-Lazaro,M.; W illmore,E.; Austin, C.A. Cells lacking DNA topoisomerase II beta are resistant to genistein, J. Nat. Prod. 2007,70(5),763-767. http:\/\/dx.doi.org\/10.1021\/np060609z PMID: 17411092","journal-title":"Nat.Prod"},{"key":"ref=195","doi-asserted-by":"publisher","first-page":"44.","DOI":"10.1186\/1472-6882-7-44","volume":"7","author":"Rhode,J.","year":"2007","unstructured":"Rhode,J.; Fogoros,S.; Zick,S.; Wahl,H.; Griffith, K.A.; Huang,J.; Liu, J.R. Ginger inhibits cell growth and modulates angiogenic factors in ovarian cancer cells. BMC Complement. Altern. Med. 2007,7,44. http:\/\/dx.doi.org\/10.1186\/1472-6882-7-44 PMID: 18096028","journal-title":"BMC Complement.Altern.Med"},{"key":"ref=196","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.biocel.2010.09.011","volume":"43(3)","author":"Bava, S.V.","year":"2011","unstructured":"Bava, S.V.; Sreekanth, C.N.; Thulasidasan, A.K.; Anto, N.P.; Cheriyan, V.T.; Puliyappadamba, V.T.; Menon, S.G.; Ravichandran, S.D.; Anto, R.J. Akt is upstream and MAPKs are downstream of NF-?B in pac litaxel-induced survival signaling events, which are down-regulated by curcumin contributing to their synergism. Int, J. Biochem. Cell Biol. 2011,43(3),331-341. http:\/\/dx.doi.org\/10.1016\/j.biocel.2010.09.011 PMID: 20883815","journal-title":"Int, J.Biochem.Cell Biol"},{"key":"ref=197","doi-asserted-by":"publisher","first-page":"3139","DOI":"10.1038\/onc.2011.23","volume":"30(28)","author":"Sreekanth, C.N.","year":"2011","unstructured":"Sreekanth, C.N.; Bava, S.V.; Sreekumar,E.; Anto, R.J. Molecular evidences for the chemosensitizing efficacy of liposomal curcumin in paclitaxel chemotherapy in mouse models of cervical cancer. Oncogene. 2011,30(28),3139-3152. http:\/\/dx.doi.org\/10.1038\/onc.2011.23 PMID: 21317920","journal-title":"Oncogene"},{"key":"ref=198","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1021\/mp800240j","volume":"6(3)","author":"Ganta,S.","year":"2009","unstructured":"Ganta,S.; Amiji, M. Coadministration of Paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. Mol. Pharm. 2009,6(3),928-939. http:\/\/dx.doi.org\/10.1021\/mp800240j PMID: 19278222","journal-title":"Mol.Pharm"},{"key":"ref=199","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1158\/0008-5472.CAN-08-2367","volume":"69(3)","author":"Beevers, C.S.","year":"2009","unstructured":"Beevers, C.S.; Chen,L.; Liu,L.; Luo,Y.; Webster, N.J.; Huang, S. Curcumin disrupts the Mammalian target of rapamycin-raptor complex. Cancer Res. 2009,69(3),1000-1008. http:\/\/dx.doi.org\/10.1158\/0008-5472.CAN-08-2367 PMID: 19176385","journal-title":"Cancer Res"},{"key":"ref=200","author":"R avindran,J.","unstructured":"R avindran,J.; Prasad,S.; Aggarwal, B.B. Curcumin and cancer cells: how many ways can curry kill tumor cells selectively? AAPS J. 2009,11(3),495-510. http:\/\/dx.doi.org\/10.1208\/s12248-009-9128-x PMID: 19590964"},{"key":"ref=201","doi-asserted-by":"publisher","first-page":"2883.","DOI":"10.3390\/molecules24162883","volume":"24(16)","author":"Choi,J.","year":"2019","unstructured":"Choi,J.; Moon,S.; Bae,H.; Kim, Y.W.; Lee,D.; Kim,S.; Seo,Y.; Wang, H.S.; Choi, Y.W.; Lee, M.W.; Ko, J.H.; Lim,I.; Bang, H. Alnus sibirica extracts suppress the expression of inflammatory cytokines induced by lipopolysaccharides, tumor necrosis factor-alpha, and interferon-gamma in human dermal fibroblasts. Molecules. 2019,24(16),2883. http:\/\/dx.doi.org\/10.3390\/molecules24162883 PMID: 31398908","journal-title":"Molecules"},{"key":"ref=202","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1074\/jbc.M113.513879","volume":"289(3)","author":"Farrand,L.","year":"2014","unstructured":"Farrand,L.; Kim, J.Y.; Byun,S.; Im-aram,A.; Lee,J.; Suh, J.Y.; Lee, K.W.; Lee, H.J.; Tsang, B.K. The diarylheptanoid hirsutenone sensitizes chemoresistant ovarian cancer cells to cisplatin via modulation of apoptosis-inducing factor and X-linked inhibitor of apoptosis, J. Biol. Chem. 2014,289(3),1723-1731. http:\/\/dx.doi.org\/10.1074\/jbc.M113.513879 PMID: 24247248","journal-title":"Biol.Chem"},{"key":"ref=203","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1177\/1534735403261831","volume":"3 (1)","author":"Keck, A.S.","year":"2004","unstructured":"Keck, A.S.; Finley, J.W. Cruciferous vegetables: cancer protective mechanisms of glucosinolate hydrolysis products and selenium. Integr. Cancer Ther. 2004,3 (1),5-12. http:\/\/dx.doi.org\/10.1177\/1534735403261831 PMID: 15035868","journal-title":"Integr.Cancer Ther"},{"key":"ref=204","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jnutbio.2004.10.007","volume":"16(2)","author":"Kim, Y.S.","year":"2005","unstructured":"Kim, Y.S.; Milner, J.A. Targets for indole-3-carbinol in cancer prevention, J. Nutr. Biochem. 2005,16(2),65-73. http:\/\/dx.doi.org\/10.1016\/j.jnutbio.2004.10.007 PMID: 15681163","journal-title":"Nutr.Biochem"},{"key":"ref=205","doi-asserted-by":"publisher","first-page":"166","DOI":"10.2174\/1876142911002020166","volume":"2(2)","author":"Acharya,A.","year":"2010","unstructured":"Acharya,A.; Das,I.; Singh,S.; Saha, T. Chemopreventive properties of indole-3-carbinol, diindolylmethane and other constituents of cardamom against carcinogenesis. Recent Pat. Food Nutr. Agric. 2010,2(2),166-177. http:\/\/dx.doi.org\/10.2174\/1876142911002020166 PMID: 20653562","journal-title":"Recent Pat.Food Nutr.Agric"},{"key":"ref=206","first-page":"387","volume":"24(4)","author":"Bradlow, H.L.","year":"2010","unstructured":"Bradlow, H.L.; Zeligs, M.A. Diindolylmethane (DIM)  spontaneously forms from indole-3-carbinol (I3C)  during cell culture experiments. In Vivo. 2010,24(4),387-391. PMID: 20668304","journal-title":"In Vivo"},{"key":"ref=207","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1002\/bdd.759","volume":"32(5)","author":"Saw, C.L.","year":"2011","unstructured":"Saw, C.L.; Cintr\u00f3n,M.; Wu, T.Y.; Guo,Y.; Huang,Y.; Jeong, W.S.; Kong, A.N. Pharmacodynamics of dietary phytochemical indoles I3C and DIM: Induction of Nrf2-mediated phase II drug metabolizing and antioxidant genes and synergism with isothiocyanates. Biopharm. Drug Dispos. 2011,32(5),289-300. http:\/\/dx.doi.org\/10.1002\/bdd.759 PMID: 21656528","journal-title":"Biopharm.Drug Dispos"}],"container-title":["Current Topics in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/180933","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/180933\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/180933","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,4]],"date-time":"2021-01-04T15:35:49Z","timestamp":1609774549000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/180933\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,17]]},"references-count":206,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2020,8,17]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1568026620666200416084440","relation":{},"ISSN":["1568-0266"],"issn-type":[{"value":"1568-0266","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8,17]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-12-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-05","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}